

Total biosynthesis of the cyclic AMP booster forskolin from *Coleus forskohlii*

Irini Pateraki^{1,2,§*}, Johan Andersen-Ranberg^{1,2,†,§}, Niels Bjerg Jensen³, Sileshi Gizachew Wubshet^{4,†}, Allison Maree Heskes^{1,2}, Victor Forman¹, Björn Hallström⁵, Britta Hamberger^{1,2,†}, Mohammed Saddik Motawia^{1,2}, Carl Erik Olsen^{1,2}, Dan Staerk⁴, Jørgen Hansen³, Birger Lindberg Møller^{1,2} and Björn Hamberger^{1,2,†}

¹Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Denmark;

²Center for Synthetic Biology “bioSYNergy”, Copenhagen, Denmark;

³Evolva A/S, Copenhagen, Denmark;

⁴Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark;

⁵Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden;

[†]current addresses:

JAR, Department of Plant & Microbial Biology, University of California, Berkeley, 111 Koshland Hall, Berkeley, CA, 94720;

SGW, Nofima AS, Osloveien 1, N-1430 Ås, Norway

BjH, BrH; Department of Biochemistry & Molecular Biology, Michigan State University, Molecular Plant Sciences Building, 1066 Bogue Street, East Lansing, MI 48824, USA

[§]These authors have contributed equally to the article

*Correspondence to: Irini Pateraki, eipa@plen.ku.dk

Abstract (150)

Forskolin is a unique structurally complex labdane type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant *Coleus forskohlii*, in which forskolin accumulates in the root cork. Here we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13*R*-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13*R*-manoyl oxide into forskolin as demonstrated by transient expression in *Nicotiana benthamiana*. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into *Saccharomyces cerevisiae* and afforded forskolin titers of 40 mg/L.

Introduction

Plants synthesize an impressive diversity of specialized metabolites enabling them to communicate and adapt to environmental challenges (*Mithöfer et al., 2012; Woldemariam et al., 2011*). Throughout history, humans have benefited from the medicinal properties of many of these phytochemicals (*Hardy et al., 2012*). Specialized plant metabolites and direct derivatives thereof still constitute more than a third of approved pharmaceuticals (*Cragg et al., 2013; David et al., 2015*). With over 50,000 known structures according to the “Dictionary of natural products”

(<http://dnp.chemnetbase.com/>), terpenoids are the largest class of plant specialized metabolites and constitute a vast repository of bio-active natural products including many structurally complex compounds (**Pateraki et al., 2015**). Examples of widely used plant derived terpenoid pharmaceuticals are the anti-cancer drug paclitaxel (taxol®) (**Liu et al., 2010**), the therapeutic ingenol mebutate (picato®) that is used for treatment of actinic keratosis (**King et al., 2016; Luo et al., 2016**) and artemisinin which is the most efficient treatment against malaria caused by *Plasmodium* parasites (**Graham et al., 2010; Paddon et al., 2014**). Traditional chemical synthesis of plant derived diterpenoid pharmaceuticals remains economically challenging, despite recent examples of elegant strategies mimicking natural routes (**Appendino 2014; Kawamura et al., 2016; Yuan et al., 2016**). Extraction from plant biomass and semi-synthesis from biotechnologically produced intermediates have been approached as alternative strategies (**Graham et al., 2010; Paddon et al., 2013; Roberts 2007**). In contrast to recent examples demonstrating complete pathway reconstruction and production of opiate alkaloids in yeast (**Galanie et al., 2015; Nakagawa et al., 2016**), engineered total biosynthesis of terpenoid therapeutics—including paclitaxel and ingenol esters—has not yet been achieved. Challenges on the way to achieving this goal include the identification of pathway enzymes in native systems, particularly for those belonging to multi-enzyme families catalyzing the biosynthesis of specialized metabolites in plants, engineering of poorly understood multi-step enzymatic pathways and difficulties encountered in heterologous expression of key enzymes catalyzing monooxygenations critical for diterpenoid biosynthesis (**Pateraki et al., 2015; Renault et al., 2014**).

The diterpenoid forskolin is the active hypotensive principle accumulating in the root cork of *Coleus forskohlii* (**Pateraki et al., 2014**), a perennial shrub of the Lamiaceae family, indigenous to India and Southeast Asia with numerous reported applications in traditional medicine (**Alasbahi et**

al., 2010b; Kavitha et al., 2010). The pharmaceutical properties of forskolin are based on its ability to directly activate adenylate cyclase enzyme resulting in elevated levels of the second messenger cyclic adenosine monophosphate (cAMP) (Doseyici et al., 2014; Seamon et al., 1981). Approved applications of forskolin range from alleviation of glaucoma (Ocufores™ Eye drop solutions, Sabinsa, India), treatment of hypertension and heart failure (Colforsin daropate hydrochloride, a water-soluble derivative of forskolin, Nippon Kayaku, Japan) to lipolysis and body weight control (Godard et al., 2005; Kikura et al., 2004; Toya et al., 1998; Wagh et al., 2012; Yoneyama et al., 2002). Therapeutic opportunities were also suggested in animal tests, where forskolin induced pigmentation of the skin, increasing protection against UV-associated carcinogenesis (D'Orazio et al., 2006). The complex chemical structure of forskolin with a decalin core characteristic of labdane type diterpenoids, a tetrahydropyran ring, five oxidized positions and eight chiral centers (Figure 1A) represents a challenge for classical organic chemical synthesis, although a key intermediate for stereoselective total synthesis has been reported (Ye et al., 2009). Hence, commercially available forskolin is extracted from *C. forskohlii* roots and purified from a mixture of over 60 structurally related abietane and epoxylabdane diterpenoids with a forskolin content varying from 0.013 % to 0.728 % of root dry weight (Alasbahi et al., 2010a; Asada et al., 2012; Srivastava et al., 2017). As the demand for forskolin grows, reliable and sustainable commercial production from *C. forskohlii* will become unachievable due to low yields, susceptibility of this species to diseases, changing climatic conditions and the resource intensive extraction and purification procedure required to obtain pharmaceutical grade forskolin (Mora-Pale et al., 2014). Elucidation of the biosynthetic pathway to forskolin and subsequent engineering of the pathway into microbial hosts offers a cleaner and more stable alternative production system that will be better able to address future needs.

91 Recently, we reported specific accumulation of forskolin and its diterpene scaffold 13R-manoyl
92 oxide in the root cork cells of *C. forskohlii*. A pair of diterpene synthases (*CfTPS2* and *CfTPS3*),
93 exclusively present in the root cork, was found to catalyze cyclization of the C₂₀ diterpenoid
94 precursor geranylgeranyl diphosphate (GGPP) into 13R-manoyl oxide, the diterpene scaffold of
95 forskolin (**Pateraki et al., 2014**). As a proof of concept, biosynthesis of 13R-manoyl oxide in
96 enantiomerically pure form but in low yields was achieved by expressing *CfTPS2* and *CfTPS3* in
97 *Saccharomyces cerevisiae*, *E. coli* and *Synechocystis* sp. (**Andersen-Ranberg et al., 2016; Englund**
98 **et al., 2015; Nielsen et al., 2014**). Taking into account the functionalization steps needed for
99 conversion of 13R-manoyl oxide to forskolin (**Figure 1A**), involvement of enzymes from the
100 families of cytochrome P450s (CYPs) and acetyltransferases would be predicted.

101 Here we report an integrated biochemical and functional genomics approach, including
102 metabolomics, single cell-type transcriptome studies and a synthetic biology modular approach
103 involving transient combinatorial expression of candidate genes in *Nicotiana benthamiana* to
104 identify the panel of enzymes catalyzing functionalization of the *C. forskohlii* diterpene backbones
105 and more specifically the biosynthesis of forskolin. Pathway intermediates were identified using
106 GC- or HPLC-HRMS-SPE-NMR. To demonstrate the downstream application of the present work
107 regarding biotechnological production of forskolin, the entire forskolin biosynthetic pathway was
108 reconstituted in engineered *Saccharomyces cerevisiae* for fermentation-based production of
109 forskolin from glucose. Forskolin is the first example of a pharmaceutical diterpenoid produced
110 entirely in yeast at titers relevant for industrial consideration. The outlined combinatorial
111 biochemistry approach paves the way for development of yeast-engineered platforms for
112 biosynthesis of other known or new-to-nature diterpenoids

113

114 **Results**

115

116 **Discovery of multifunctional cytochromes P450 in *Coleus forskohlii* producing a multitude of**
117 **13*R*-manoyl oxide-derived diterpenoids and identification of a biosynthetic pathway for**
118 **forskolin.**

119 The conversion of 13*R*-manoyl oxide to forskolin requires six regio- and stereospecific
120 monooxygenations and a single regiospecific acetylation (**Figure 1A**). Considering the strict
121 localization of forskolin in the root cork cells of *C. forskohlii* and the almost exclusive expression of
122 the pair of diterpene synthases forming 13*R*-manoyl oxide within the same tissue (**Pateraki et al.,**
123 **2014**), the root cork was selected for deep RNA-Seq transcriptome analysis. The generated
124 transcriptome contained 263,652 assembled putative cDNAs. The transcriptome was queried for
125 transcripts encoding cytochrome P450s belonging to the CYP71 clan, based on their established
126 role in monooxygenation reactions in the biosynthesis of specialized metabolites (**Nelson 2013;**
127 **Werck-Reichhart et al., 2000**). Their relative levels in the root cork transcriptome were also taken
128 into consideration. Within the CYP71 clan, focus was also placed on P450 subfamilies that showed
129 extensive, recent expansions in the cork transcriptome (**Nelson et al., 2011; Werck-Reichhart et**
130 **al., 2000**). Cytochrome P450 members of the CYP76AH subfamily, part of the CYP71 clan, have
131 recently been shown to catalyze monooxygenation of abietane-type diterpenoids like miltiradiene
132 and dehydroabietadiene in Lamiaceae species, closely related to *C. forskohlii* (**Božić et al., 2015;**
133 **Ignea et al., 2016a; Zi et al., 2013**). Members of this P450 subfamily were therefore of high
134 interest as enzymes putatively involved in diterpenoid biosynthesis in *C. forskohlii*. Based on these

considerations, a total of 29 cytochrome P450 candidates (**Figure 1-source data 1**) were selected and cloned in full length from cDNA synthesized from root cork total RNA. Among these CYPs, seven members were assigned to the CYP76AH subfamily by the “P450 Nomenclature committee” (**Nelson 2009**), rendering this CYP subfamily the highest represented in the transcriptome (**Figure 1-source data 1**). Five were full length sequences (*CfCYP76AH8*, *CfCYP76AH9*, *CfCYP76AH10*, *CfCYP76AH11*, and *CfCYP76AH11*), while two (*CfCYP76AH15* and *CfCYP76AH16*) were represented by partial cDNAs. For the latter, 5’RACE experiments afforded the full-length cDNAs. Similarly to the previously identified diTPSs, *CfTPS2* and *CfTPS3* (**Pateraki et al., 2014**), gene expression studies showed that the identified members of the CYP76AH family were highly or exclusively expressed in the root cork cells (**Figure 1B**).

We have recently reported an *Agrobacterium* mediated modular transient expression system in *Nicotiana benthamiana* enabling biosynthesis of labdane-type diterpenes in quantities permitting purification and structural elucidation (**Andersen-Ranberg et al., 2016**). Utilizing this system, each of the candidate P450 genes were heterologously expressed in combination with genes necessary for the production of high amounts of 13*R*-manoyl oxide (**Andersen-Ranberg et al., 2016; Pateraki et al., 2014**). Of the CYPs tested, six efficiently converted 13*R*-manoyl oxide into oxygenated derivatives (**Figure 2A, 3 and Figure 3-supplement 1 and 2**). *CfCYP76AH15*, *CfCYP76AH8* and *CfCYP76AH17* catalyzed formation of 11-oxo-13*R*-manoyl oxide (**2**) as the main product (**Figure 2 and 3**). The structure of forskolin harbors a keto-group at the C-11 position and this also applies for the majority of 13*R*-manoyl oxide-derived diterpenoids found in *C. forskohlii* (**Asada et al., 2012; Zhang et al., 2009**). Of the three CYP76AHs tested in this experiment, *CfCYP76AH15* showed the highest efficiency and specificity for the conversion of 13*R*-manoyl oxide to **2** with no concomitant formation of multi-oxygenated products (**Figure 2**). Compound **5d** produced by

CfCYP76AH8 as well as by *CfCYP76AH17* was identified as 1,11-dihydroxy-13*R*-manoyl oxide (**Figures 2B, 4 and Table 1 and 2**). This specific oxygenation pattern is also found in forskolin. Minor amounts of several di- and trihydroxylated 13*R*-manoyl oxide-derived compounds were also produced by *CfCYP76AH8* and *CfCYP76AH17* (**Figure 2A and Figure 3-Figure Supplement 1**). Although we managed to identify the chemical structures of a number of 13*R*-manoyl oxide derivatives (**Figure 2B**), it was not possible to do so the procedure for all the compounds shown in **Figure 3-Figure Supplement 1**. The main obstacle was the high complexity of the diterpenoids produced in *N. benthamiana* leaves expressing the *CfCYP76AHs* as well as the small amounts present of most of these diterpenoids. Additional limiting factors were the instability of several these compounds and the limiting plant material available. Production of higher amounts of the compounds in microbial hosts was not pursued, because the terpenoid profiles observed following expression of the enzymes in plants and yeast cells were not identical.

Two additional CYPs of the CYP76AH subfamily catalyzed oxygenation of 13*R*-manoyl oxide at different positions without substantial formation of C-11 keto derivatives. *CfCYP76AH16* yielded predominantly **3a** which was identified by NMR as 9-hydroxy-13*R*-manoyl oxide (or coleorol) and *CfCYP76AH11* produced a range of monooxygenated derivatives including traces of **10b** which was identified by NMR as 9-deoxydeacetylforskolin (**Figure 2**). The positions of the carbonyl and hydroxyl-groups in **3a** and **10b** were consistent with those in forskolin. Thus the individual activities of the CYPs catalyzing formation of these compounds can be considered complementary in forskolin biosynthesis: **10b** carries the carbonyl-function at C-11 and the three hydroxyl groups observed in forskolin at positions C-1, C-6 and C-7, but lacks hydroxylation at the C-9 position, which is observed in **3a**. The only enzyme outside the CYP76AH subfamily that displayed activity

towards 13*R*-manoyl oxide was CYP71D381, which resulted in oxidized derivatives at positions not compatible with forskolin (**Figure 3-Figure Supplement 2**).

To probe the role of the different CYP76AH enzymes in forskolin biosynthesis, they were co-expressed by combining one of the three P450s catalyzing formation of **2** with the functionally distinct *Cf*CYP76AH11 and *Cf*CYP76AH16, first in pairs, then in all possible permutations as triplets (**Figure 5 and Figure 5-Figure Supplement 1**). The combination of *Cf*CYP76AH15 and *Cf*CYP76AH11 afforded production of 6,7-dihydroxy-11-keto-manoyl oxide (**7h**) as part of a complex mixture. Formation of **7h** demonstrated combined introduction of the carbonyl group at C-11 together with two hydroxyl groups at positions C-6 and C-7, again consistent with the oxygenation pattern of forskolin (**Figure 2 and Figure 5-Figure Supplement 1**).

When the CYP76AH enzymes were assayed in triplet combinations, the product profiles were further shifted towards multi-oxygenated 13*R*-manoyl oxide derivatives. The formation of minor amounts of deacetylforskolin (**13b**) and several compounds with identical mass to charge ratio (*m/z*) but different retention times were detected using different enzyme combinations (**Figure 5, Table 3**). The triplet combination *Cf*CYP76AH15, *Cf*CYP76AH11 and *Cf*CYP76AH16 led to the highest amounts of **13b**. Thus, this combination of multifunctional P450s appeared to constitute the optimal biosynthetic pathway for specific formation of **13b** from **1** using the engineering approaches of synthetic biology (**Figure 5**).

Monooxygenase activity of the CYP76AH subfamily towards other terpene scaffolds

In addition to 13*R*-manoyl oxide-derived diterpenoids, the root cork of *C. forskohlii* contains numerous abietane diterpenoids derived from miltiradiene (*Alasbahi et al., 2010a*). Recently a

pair of diterpene synthases (*Cf*TPS1 and *Cf*TPS3) mainly expressed in the root cork of *C. forskohlii* was demonstrated to produce miltiradiene (**Pateraki et al., 2014**). It has been shown previously that members of the CYP76AH subfamily in Lamiaceae are able to oxygenate miltiradiene or derivatives thereof. CYP76AH1 from *Salvia miltiorrhiza* (**Guo et al., 2013**), CYP76AH4 as well as RoFS1 and RoFS2 from *Rosmarinus officinalis* (**Božić et al., 2015; Zi et al., 2013**) and CYP76AH24 from *S. pomifera* catalyze synthesis of ferruginol, the precursor of carnosic acid and tanshinones (**Guo et al., 2013; Ignea et al., 2016a**), from miltiradiene or dehydroabietadiene. Additionally, CYP76AH3 from *S. miltiorrhiza* has been shown to accept ferruginol as a substrate to produce sugiol, 11-hydroxy-ferruginol and 11-hydroxy-sugiol (**Guo et al., 2015**). These miltiradiene-accepting CYP76AHs show high sequence homology, ranging from 60% to 85% at the amino acid level, with those identified in *C. forskohlii*. Therefore, it was tempting to study the ability of the *Cf*CYP76AHs to metabolize miltiradiene. The *Cf*CYP76AHs were co-expressed individually in *N. benthamiana* leaves producing miltiradiene (**Andersen-Ranberg et al., 2016**), and the product profile monitored by unbiased LC-MS analysis. *Cf*CYP76AH15 was shown to convert miltiradiene to ferruginol (**Figure 6**). Ferruginol was identified in extracts of *C. forskohlii* root cork (**Figure 6**), so it is possible that *Cf*CYP76AH15 is also involved in the biosynthesis of ferruginol *in planta*. In a parallel series of experiments, CYP76AHs from rosemary and salvia known to accept miltiradiene as substrate were tested for their ability to use 13*R*-manoyl oxide as a substrate. Transient expression of RoCYP76AH4 (**Zi et al., 2013**), RoFS1 and SfFS (**Božić et al., 2015**) in *N. benthamiana* leaves able to synthesize 13*R*-manoyl oxide (**Pateraki et al. 2014**) demonstrated that RoCYP76AH4 efficiently converted 13*R*-manoyl oxide to 11-oxo-13*R*-manoyl, while RoFS1 and SfFS, in addition to 11-oxo-13*R*-manoyl produced 11-hydroxy manoyl oxide (**Figure 7**).

Establishing regiospecific acetylation as the final step of forskolin biosynthesis

To complete the biosynthetic route to forskolin, specific acetylation of the C-7 hydroxyl group of deacetylforskolin (**13b**) is required. The root cork transcriptome was mined for acyltransferases (ACTs) from clade III of the BAHD family earlier reported to predominantly use acetyl CoA as acetyl donor for acetylation of hydroxyl groups (D'Auria 2006). Ten ACTs (Figure 1-source data 1) were identified, cloned and tested functionally by *Agrobacterium*-mediated transient expression in *N. benthamiana* leaves, engineered to produce deacetylforskolin by co-expression of the enzymes CfDXS, CfGGPPS, CfTPS2, CfTPS3, CfCYP76AH15, CfCYP76AH11 and CfCYP76AH16. Two ACT candidates, CfACT1-6 and CfACT1-8, were found to catalyze acetylation of **13b** (Figure 8). Expression of CfACT1-6 resulted in formation of a broad range of acetylated products of which forskolin constituted a minor fraction. In contrast, CfACT1-8 exhibited high activity and specificity, with efficient conversion of **13b** to forskolin and absence of detectable acetylated side products. This establishes the entire and highly specific biosynthetic route to forskolin from its precursor, GGPP (Figure 9).

Engineering of the entire pathway of forskolin in *Saccharomyces cerevisiae*

Expression and engineering of plant biosynthetic pathways in microbial organisms provides a method for sustainable production of high value compounds like the structurally complex bioactive diterpenoids (Guo et al., 2013; Ignea et al., 2016a; Jia et al., 2016). With the genes encoding the entire biosynthetic pathway of forskolin identified, we proceeded to establish stable forskolin production in *S. cerevisiae*, an excellent host organism for biosustainable and scalable

246 production of numerous bio-active natural products (*Brochado et al., 2010; Brown et al., 2015;*
247 *Galanie et al., 2015; Hansen et al., 2009; Ignea et al., 2016a; Jeandet et al., 2012*). For expression
248 in yeast, all *C. forskohlii* genes were codon-optimized and stably integrated in neutral loci in the
249 yeast genome. Genomic integration was chosen versus expression via episomal plasmids as the
250 former strategy favors the simultaneous expression of a large number of genes as well as effective
251 selection marker recycling (*Jensen et al., 2014*). Additionally, a sequence encoding a NADPH-
252 dependent cytochrome P450 oxidoreductase (*CfPOR*), required to support the P450 activity, was
253 identified from the *C. forskohlii* root cork transcriptome and cloned for co-integration in the yeast
254 genome. The isolated *CfPOR* was the only one present in the root cork transcriptome. Genomic
255 integration enabled stable, simultaneous expression of a total of nine heterologous genes in the
256 microbial host.

257 *CfPOR*, *CfCYP76AH15*, *CfCYP76AH11*, *CfCYP76AH16* and *CfACT1-8* were co-expressed in the yeast
258 strain EFSC4498, previously engineered to produce 350 mg/L 13*R*-manoyl oxide (*Andersen-*
259 *Ranberg et al., 2016*). Transformed yeast strains verified for the integration of all forskolin
260 biosynthetic cDNAs into their genome, were further analyzed and production titers of forskolin
261 and pathway intermediates were monitored. The highest forskolin producing strain, EVST21543,
262 demonstrated genetic stability through several rounds of cultivation and was grown in a 5 L
263 fermenter using minimal medium under glucose limited conditions. During fermentation,
264 accumulation of forskolin (**16c**), 13*R*-manoyl oxide (**1**), 9-hydroxy-13*R*-manoyl oxide (**3a**), and
265 biomass formation (**Figure 10**) were monitored over time. Forskolin levels reached more than 40
266 mg/L of yeast culture. Simultaneous accumulation of high titers of 13*R*-manoyl oxide (**1**) and 9-
267 hydroxy-13*R*-manoyl oxide (**3a**) at levels of 200 and 500 mg/L of yeast culture, respectively,
268 indicated that the conversion of 13*R*-manoyl oxide (**1**) to forskolin was far from complete. These

intermediates did not accumulate in the *C. forskohlii* root cork. A comparison of the total intermediate profiles of *C. forskohlii* root cork versus the fermenter grown EVST21543 yeast strain is shown in (**Figure 10-Figure Supplement 1**).

Discussion

The terpenoid biosynthetic pathways active in the root of *C. forskohlii* produce an array of 13*R*-manoyl oxide and miltiradiene-derived diterpenoids, including forskolin. Forskolin is one of the most complex and highly oxygenated diterpenoids reported in *C. forskohlii*. In the current study, the genes encoding the entire biosynthetic pathway for forskolin were identified. Availability of the transcriptome from the root cork cells of *C. forskohlii*, where forskolin biosynthesis takes place, the option to achieve rapid functional characterization of the gene candidates *in planta* by transient expression in *N. benthamiana* and high sensitivity techniques for structural characterization made the pathway elucidation possible. With the genes encoding the entire forskolin biosynthetic pathway in hand, we achieved *de novo* production of forskolin in engineered yeast was achieved.

Initially, a number of genes encoding CYP76AH subfamily members, expressed mainly in the root cork of *C. forskohlii*, was cloned and transiently expressed in *N. benthamiana* leaves being able to produce 13*R*-manoyl oxide. The products profiles obtained with these enzymes revealed that CfCYP76AHs have discrete roles in forskolin biosynthesis. Efficient monooxygenation at C-11 is catalyzed mainly by CfCYP76AH15 (but also by CfCYP76AH8, CfCYP76AH17 and CfCYP76AH11).

290 Monooxygenation at position C-9 is catalyzed exclusively by CfCYP76AH16 and monooxygenation
291 at C-1, C-6 and C-7 mainly by CfCYP76AH11. Monooxygenation at C-1 was also observed using
292 CfCYP76AH8 and CfCYP76AH17 (**4c**, **Figure 3-Figure Supplement 1**). Collectively this set of data
293 displays the multifunctional roles of these enzymes. Together they could account for all the
294 oxygenated positions in forskolin. Co-expression of CfCYP76AH15, CfCYP76AH11 and CfCYP76AH16
295 resulted in specific and efficient formation of the final intermediate, deacetylforskolin.

296 Despite the complementary multifunctionality of the CYP76AH enzymes, partial functional
297 redundancy is possible, as demonstrated by the varied oxygenation patterns observed in
298 experiments with single enzymes. Overlapping functionalities may contribute to a coordinated
299 action for efficient conversion of **1** to **13b**. Moreover, certain *C. forskohlii* CYP76AH enzymes seem
300 able to accept oxygenated forms of **1** as substrates which results in the observed shifts in profile
301 towards higher decorated products when they are co-expressed in *N. benthamiana* (**Table 3**).

302 Although co-expression of CYP76AH11 and CYP76AH16 with either one of the three CYP76AH8,
303 CYP76AH17 or CYP76AH15 in the engineered system resulted in biosynthesis of deacetylforskolin
304 (**13b**) (**Figure 5**), the precise sequence of *in planta* 13*R*-manoyl oxide oxygenations cannot be
305 deduced from the experimental results partly because all identified CfCYP76AHs accept **1** as
306 substrate. The co-expression of the CYP76AH encoding genes in the root cork of *C. forskohlii* and
307 their partial functional redundancy or complementarity may *in vivo* constitute the basis for the
308 chemical diversity of labdane terpenoids present in the root cork of *C. forskohlii*. *In planta*, the
309 forskolin biosynthetic pathway would thus appear to be entangled within a metabolic grid offering
310 simultaneous production of a multitude of other diterpenoids.

Recently CYP76AH enzymes accepting miltiradiene as substrate were reported from other Lamiaceae species (*Božić et al., 2015; Guo et al., 2015; Ignea et al., 2016a; Zi et al., 2013*), a non-epoxylabdane, abietane diterpenoid, which is also present in *C. forskohlii* roots. This prompted us to examine whether the promiscuous and multifunctional CfCYP76AH could accept miltiradiene as substrate, and vice versa, e.g. if different Lamiaceae CYP76AHs can catalyze oxygenations of 13*R*-manoyl oxide (**Figure 6 and 7**). CfCYP76AH15 was found to have very similar catalytic activities compared to the rosemary CYP76AH4, an enzyme with a suggested role in biosynthesis of ferruginol from miltiradiene (*Zi et al., 2013*). Efficient formation of ferruginol as well as 11-oxo-13*R*-manoyl oxide, by both enzymes indicates that they may represent orthologues. Two additional ferruginol synthases of the CYP76AH subfamily, one from *Salvia fruticosa* (SfFS) and one from *Rosemary officinalis* (RoFS), were found to catalyze the conversion of 13*R*-manoyl oxide to 11-oxo-13*R*-manoyl oxide and 11-hydroxy-manoyl oxide when expressed in *N. benthamiana* leaves (**Figure 6 and 7**). These findings are not reflected in the phylogenetic analysis of the known CYP76AHs. All *C. forskohlii* CYP76AHs able to produce 11-oxo-13*R*-manoyl oxide are clustered together, while CYP76AHs from *Salvia* spp. and *R. officinalis* that can catalyze the formation of the same compound, as well as those CYPs able to accept miltiradiene as substrate, form a different cluster when analyzed with currently known CYP76AHs. Thus, it is likely that the ability of CYP76AHs to catalyze 11-oxo-13*R*-manoyl oxide has evolved convergently in these plants (**Figure 11**).

These data highlight the functional versatility of the CYP76 family. The enzymes can exhibit broad substrate specificity which may advance metabolic evolution as they provide metabolic plasticity and flexibility affording synthesis of new diterpenoids. This facilitates the expansion of the number of possible diterpenoids produced in nature and potentially serves to diversify and augment the phytochemical defense of plants. The promiscuity of the CYP76AHs also provides potentials for

their use in combinatorial approaches for synthesizing a range of diterpenoids with pharmaceutical relevance. The exclusive presence of the CYP76AH subfamily in Lamiaceae species may reflect gene duplications in a Lamiaceae ancestral species and expansion and neofunctionalization after speciation (**Figure 11**).

The identification of *Cf*ACT1-8 as an ACT catalyzing regiospecific acetylation of deacetylforskolin (**13b**) to afford forskolin completed the entire biosynthetic pathway for forskolin from its precursor, GGPP. Interestingly, the only currently identified acyltransferases in diterpenoid biosynthesis are those involved in biosynthesis of paclitaxel. Those acetyltransferases show substantial regioselective promiscuity (*Ondari et al., 2008; Walker et al., 2000*) and belong to Clade V (*D'Auria 2006; Tuominen et al., 2011*), whereas the majority of the ACTs identified in the root cork transcriptome of *C. forskohlii*, including ACT1-6 and ACT1-8, belong to Clade III (**Figure 12**).

With all forskolin biosynthetic pathway genes identified, we moved to the generation of a stable forskolin producing *S. cerevisiae* strain. To engineer a stable microbial production platform, we proceeded to integrate the minimum required set of functional parts into the *S. cerevisiae* genome. Specific *de novo* production of the highly functionalized diterpenoid from glucose at titers above 40 mg/L was achieved through a pathway consisting of a total of 10 enzymatic steps catalyzed by 7 heterologously co-expressed enzymes. This high forskolin titer, achieved with no optimization steps, highlights the potential to develop a microbial manufacturing platform for efficient and stereospecific production of forskolin with further fine-tuning of the biosynthetic pathway. Currently it is not possible to accurately estimate the forskolin titers necessary for industrially profitable production, as the exact commercial applications, market size and price as

well as the production cost including downstream processing cannot be determined at present. Given the knowledge gained in our present study and experiences with other compounds (*Paddon et al., 2014*) we find it realistic to aim for yields ranging from a single to double digits of gram per liter of yeast culture. To achieve higher forskolin yields, it is important upfront to ascertain a proper flux towards GGPP through the mevalonate pathway (*Kampranis et al., 2012*). Specifically for forskolin pathway, it seems clear that there is a limitation in flux through one or several of the P450s involved as we encounter accumulation of the intermediates, 300 mg/L and 500 mg/L of compounds **1** and **3a** respectively, compared to a forskolin production of 40 mg/L. Only minute amounts of deacetylforskolin. Accumulation of **1** and **3a** intermediates was not observed *in planta* (*Figure 10-Figure Supplement 1*). This signifies that the expression levels of the heterologously expressed genes are not properly balanced or that some of the CYPs have lower specific activity when inserted into a yeast membrane. In the native plant host, the pathway exhibits optimized carbon flux. P450s are notorious difficult to express in high amounts in yeast and recognized as exhibiting rather low K_{cat} values (*Jung et al., 2011; Renault et al., 2014*). Hence, to increase forskolin production in the yeast system, efforts should obviously be focused on optimizing *Cf*CYP76AHs expression and enzyme kinetics, specificity and catalytic efficiency as well as pathway scaffolding to facilitate formation of a metabolon improving pathway flux and efficiency and minimizing accumulation of pathway intermediates (*Laursen et al., 2016*). The high forskolin titers already obtained though in the engineered yeast strain highlights the potential to develop a microbial manufacturing platform for efficient and stereospecific production of forskolin and other labdane terpenoids by fine tuning the biosynthetic pathways.

A yeast based production platform constitutes a sustainable alternative to traditional crop-based production but the gains always need to be compared to yield improvements obtained by classical

or molecular breeding of the traditional host plant (**Graham et al., 2010**). The model-example from the literature and industry towards production of a pharmaceutically relevant terpenoid in *S. cerevisiae* is the sesquiterpenoid artemisinic acid, a pathway intermediate to the anti-malarial compound artemisinin (**Paddon et al., 2013**). However, this prominent model example is dependent on a costly organic chemical synthesis component to chemically convert artemisinic acid to artemisinin (**Peplow 2016**). Recent approaches of engineered *de novo* production of structurally complex diterpenoids, triterpenoids or alkaloids in microbial systems have also been limited to proof-of-concept studies, expression of partial pathways and sub-milligram yields, highlighting the challenges in synthetic biology to offer an economically realistic and sustainable alternative to isolation of the desired medicinal compounds from medicinal plants bred to produce elevated levels. The constraints to achieve high yields are connected to expression of multiple P450s and reconstruction of pathways with multiple functionally divergent steps (**Brown et al., 2015; Li et al., 2016; Zhou et al., 2015**). Strategies addressing these issues are the development of synthetic microbial consortia of *S. cerevisiae* and *E. coli*, optimization of P450s for functional expression in *E. coli*, optimization of interactions between the P450s and their reductase partner and N-terminal modifications (**Biggs et al., 2016; Laursen et al., 2016; Vazquez-Albacete et al., 2016; Zhou et al., 2015**).

Our current study demonstrates that mining for additional members of the CYP76AH family has the potential to facilitate the assembly of further optimized panels of mixed-species P450s for the biosynthesis of bioactive diterpenoids. This shows the great promise that combinatorial assembly including CYPs outside the CYP76AH subfamily may offer the opportunity to design production systems for diterpenoids that are currently inaccessible due to their exclusive presence in rare or

red-listed plants and to further expand the chemical diversity of diterpenoids to production of diterpenoids currently not known from nature.

Materials and Methods

Materials

All chemicals including forskolin were acquired from Sigma-Aldrich. An authentic standard of 13*R*-manoyl oxide was prepared as previously described (*Nielsen et al., 2014*). CYP76AH4 (**Zi et al., 2013**) was cloned from rosemary plants acquired at a local market in Copenhagen, Denmark. RoFS1 and SfFS (**Božić et al., 2015**) were kindly provided by Dr. Angelos Kanellis (University of Thessaloniki, Greece).

Chemical synthesis of deacetylforskolin

The deacetylation of forskolin has been achieved previously with the use of methanolic potassium carbonate which can provide 7-desacetylforskolin in 65 % yield (**Kosley et al., 1989**). Here we carried out the deacetylation of forskolin using a solution of methanolic ammonia solution (2M) to afford 7-desacetylforskolin quantitatively. The ¹H NMR data of the deacetylated forskolin were in agreement with the reported data in literature.

Transcriptome sequencing

Coleus forskohlii root cork total RNA was extracted as previously described (**Pateraki et al., 2014**). RNA was prepared for sequencing using the Illumina TruSeq sample preparation kit v2 using poly-A selection (Illumina San Diego, USA). The fragments were clustered on cBot and sequenced with paired ends (2 × 100bp) on a HiSeq 2500 (Illumina San Diego, USA) according to the manufacturer's instructions. A total 106.2 million read-pairs were generated. Adaptor sequences were removed from raw reads and reads were trimmed at the ends to phred score 20, using the fastq-mcf tool from ea-utils (<https://code.google.com/p/ea-utils/>). Processed reads were assembled using Trinity (r2013-02-16) resulting in a total of 263,652 assembled putative transcripts. Transcript abundance estimation was performed using RSEM and the scripts provided with Trinity. Likewise, the putative coding sequences were predicted using the TransDecoder scripts from Trinity. The high throughput RNA sequences reported here have been submitted to the short read archive (SRA) at the NCBI [accession no SAMN06013363]

Identification and cloning of genes involved in forskolin biosynthesis

Mining of the *C. forskohlii* transcriptome database was performed as previously described (**Zerbe et al., 2013**) using tBLASTx software and known cytochrome P450 (CYP) or acetyl transferase (ACT) sequences as query. The identified contigs were amplified from single stranded cDNA generated from root cork total RNA using the “SuperScript III First-Strand Synthesis System for RT-PCR” (Invitrogen) and oligo-dT primer. Cloning of the putative CYP and ACT cDNAs was achieved after PCR amplification using gene specific primers (**Figure 1-source data 3**) that were designed based on the *in silico* sequences of the identified CYP and ACT contigs (**Figure 1-source data 1**). PCR products were cloned into the pJET1.2 vector and verified by sequencing. For the identified non-

full-length cDNAs, (*CfCYP76AH15*, *CfCYP76AH16* and *CfACT1-8*), full-length transcripts were obtained using 5'RACE techniques.

Phylogenetic analysis of CYP76AH and ACT candidate enzymes

Amino acid sequences of the CYP76AHs of *C. forskohlii* and of currently available CYP76AHs from other plant species were used to construct a phylogenetic tree to infer the evolutionary history of these enzymes. Sequences were retrieved from the current work, GenBank database (<http://www.ncbi.nlm.nih.gov/>) and original articles. Peptide alignments were performed using the MUSCLE program included in the MEGA6 software. Phylogenetic analyses were performed by the Maximum Likelihood method based on the Dayhoff matrix-based model with “uniform rates” (**Schwarz et al., 1979**) and using all sites with “Nearest-Neighbor-Interchange” heuristic method conducted using MEGA6 software (**Tamura et al., 2013**). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Bootstrap values shown in % were inferred from 1000 replicates. Branches supported by bootstrap values higher than 75% are shown.

For the phylogenetic analyses of *CfACT* candidates, the identified sequences from *C. forskohlii* were analyzed together with BAHD family acyltransferase representatives from all clades (**D'Auria 2006**). The analysis includes only functionally characterized members. The analysis was inferred by using the Maximum Likelihood method based on the Dayhoff matrix-based model with “uniform rates” and using all sites (**Schwarz et al., 1979**). Initial trees for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT model, and then selecting the topology with superior log likelihood value.

The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Evolutionary analyses were conducted using MEGA6 software (*Tamura et al., 2013*).

RNA extraction and Quantitative Real-Time PCR

Total RNAs from *C. forskohlii* tissues were extracted as previously described (*Pateraki et al., 2014*) and digested by DNase I on-column. The integrity of the RNA samples was evaluated using the RNA-nano assay using an Agilent 2100 Bioanalyser (Agilent Technologies). First-strand cDNAs were synthesized from 0.5 µg of total RNA from an oligo-dT primer, using the “SuperScript III First-Strand Synthesis System for RT-PCR” (Invitrogen). The resulting cDNAs were diluted 10-fold. For the qRT-PCR reactions, gene specific primers were used (*Figure 1-source data 3*) with Maxima SYBR Green/Fluorescein qPCR Master Mix (Fermentas) on a Rotor-Gene Q cycler (Qiagen) using the following cycling parameters: 95 °C for 7 min, 35 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s followed by a melting curve cycle from 60 °C to 90 °C. Eukaryotic initiation factor 4A (TIF4a) and Elongation Factor 1A (EF1a) were used as reference genes because they showed the lowest variation across different tissues (*Pateraki et al., 2014*). No statistically significant differences were observed between the results obtained using the 2 different reference genes and the results presented were normalized based on TIF4a. Relative transcript abundance was calculated as the mean of three biological replications obtained using three different *C. forskohlii* plants, while the reactions were performed in three technical replicates. Amplification efficiency was calculated with the “Real Time PCR Miner” (<http://www.miner.ewindup.info/Version2>). Efficiency-corrected Δ CT values were used to quantify relative differences in target gene transcript accumulation. Primer specificity was assessed by agarose gel analysis and sequencing of amplicons from representative reactions, as well as from melting curve analysis of every reaction.

488

489 Functional characterization of *Coleus forskohlii* cytochrome P450 enzymes (CfCYPs) by transient
490 expression in *N. benthamiana*

491 Functional characterization of the selected candidate genes was obtained using transient
492 expression in *N. benthamiana* which offers optimal native plant protein translation and
493 processing, convenient rapid and optional combinatorial co-expression of multiple genes from
494 independent vectors, native subcellular location of diTPS and CYPs as well as the availability of an
495 endogenous native pathway providing GGPP.

496 For the functional characterization of *C. forskohlii* selected CYPs and testing of their ability to
497 hydroxylate 13*R*-manoyl oxide (**1**), genes encoding candidate CfCYPs were transiently co-
498 expressed in *N. benthamiana* leaves together with *C. forskohlii* enzymes boosting the formation of
499 **1**, namely 1-deoxy-D-xylulose 5-phosphate synthase (CfDXS), geranylgeranyl diphosphate synthase
500 (CfGGPPS), CfTPS2 and CfTPS3 (**Pateraki et al., 2014**). Transient expression in *N. benthamiana* was
501 performed as previously described (**Spanner et al., 2014**). CfCYP cDNAs selected for functional
502 testing were subcloned into pCAMBIA130035Su by USER cloning (**Nour-Eldin et al., 2010**). Vectors
503 carrying the selected cDNAs were then transformed into the agrobacterium strain AGL-1-GC3850
504 (**Spanner et al., 2014**). For the agro-infiltration, the OD of the agrobacterium cultures of all
505 transformed agrobacteria strains was normalized to OD₆₀₀ = 1. Different combinations prepared
506 from equal volumes of each culture of transformed agrobacterium strains expressing individual
507 genes encoding CfCYPs or 13*R*-manoyl oxide biosynthetic enzymes were infiltrated into the leaves
508 of 4-6 weeks old *N. benthamiana* plants. Controls encompassing expression of the CfCYP encoding
509 genes without the 13*R*-manoyl oxide biosynthetic genes were used to assess the possibility of
510 CfCYPs cross-reactivity with tobacco endogenous diterpenoids.

Metabolites from transgenic *N. benthamiana* leaves were extracted by hexane and 85% MeOH and were analyzed by GC-MS and LC-MS-qTOF, respectively. LC-MS-qTOF analysis was performed on the system that was comprised of an Agilent G1312B SL binary pump, Agilent G1367C SL WP autosampler, Agilent G1316B column oven, Agilent G1315C Starlight DAD detector and Bruker microTOF II Mass Spectrometer using Electron Spray Ionization (ESI). Samples were separated on a Synergi 2.5 mm Fusion-RP C18 column (50 × 3.2 mm i.d., Phenomenex Inc., Torrance, CA, USA) at a flow rate of 0.2 mL/min with column temperature held at 25 °C. The mobile phase consisted of water with 0.1% formic acid (v/v; solvent A) and 80% acetonitrile with 0.1% formic acid (v/v; solvent B). The gradient program was 0 min, 60% B; 25 min, 98% B; 31 min, 98% B; 32 min, 60% B; 42min, 60% B. Mass spectra were acquired in positive ion mode using a drying temperature of 200 °C, a nebulizer pressure of 3.0 bar, and a drying gas flow of 7 L/min (*Luo et al., 2016*).

GC-MS analysis was performed on a Shimadzu GCMS-QP2010 Ultra using a 3 Agilent HP-5MS column (20 m × 0.180 mm i.d., 0.18 µm film thickness). Injection volume and temperature was set to 1 µL and 250 °C. GC program: 60 °C for 1 min, ramp at rate 30 °C min⁻¹ to 180 °C, ramp at rate 10 °C min⁻¹ to 290 °C, ramp at rate 30 °C min⁻¹ to 320 °C and hold for 2 min. H₂ was used as carrier gas. Transfer line temperature was set to 280 °C and electron impact (EI) was used as ionization method in the mass spectrometer (MS) with the ion source temperature and voltage set to 300 °C and 70 eV. MS spectra were recorded from 50 m/z to 400 m/z.

Large scale biosynthesis of oxygenated 13*R*-manoyl oxide compounds for NMR analysis

11-oxo-13*R*-manoyl oxide (**2**), 2-hydroxy-13*R*-manoyl oxide (**3b**), 19-hydroxy-13*R*-manoyl oxide (**3c**), 1,11-dihydroxy-13*R*-manoyl oxide (**5d**), 1,9-deoxydeacetylforskolin (**7h**) and 9-deoxydeacetylforskolin (**10b**) were produced using the biosynthetic scheme described above by

large-scale expression of the relevant gene combinations in *N. benthamiana* (**Andersen-Ranberg et al., 2016**). *CYP76AH8* was expressed to obtain biosynthesis of compound (**2**), *CYP71D381* to obtain (**3b**) and (**3c**), whereas combined expression of *CfCYP76AH8* and *CfCYP76AH11* afforded (**5d**), (**7h**) and (**10b**). For the large-scale experiments, agroinfiltration was performed by vacuum infiltration. For biosynthesis of each compound in amounts sufficient for NMR analysis, 100-200 g of fresh weight *N. benthamiana* leaf material were harvested 7 d after infiltration. Leaf material chopped into small pieces was extracted using 0.5 L of *n*-hexane. The solvent was thrice evaporated and recovered by rotor evaporation for repeated extraction of the same leaf material. Concentrated extracts from *N. benthamiana* leaves biosynthesizing target compounds were subjected to solid phase extraction (SPE), using silica gel with *n*-hexane and ethyl acetate mixtures (100:0, 99:1, 98:2, 94:6, 92:8, 88:12 (v/v)) in steps of 100 mL. Fractions containing diterpenoids were identified by GC-MS. Diterpenoid-containing fractions were combined and the solvent removed by rotor evaporation and the samples resuspended in 1 mL *n*-hexane affording a crude fraction for further purification.

Isolation of oxygenated 13*R*-manoyl oxide-derived diterpenoids from *N. benthamiana* extracts

Final isolation of individual diterpenoids was achieved using an Agilent 7890B GC installed with an Agilent 5977A MSD, GERSTEL Preparative Fraction Collector (PFC) AT 6890/7890 and a GERSTEL CIS 4C Bundle injection port. Separation was carried out using a RESTEK Rtx-5 column (30 m × 0.53 mm i.d. × 1 µm d_f) with H₂ as carrier gas. At the column outlet, a splitter was mounted with a split vent ratio of 1:100 to the MS and the PFC, respectively. Sufficient amounts of oxidized 13*R*-manoyl oxide-derived diterpenoids for NMR analysis (0.5-1 mg) were obtained by 100 repeated injections of 5 µL extract aliquots. Injection port was set in solvent vent mode with a H₂ gas flow of 100

mL/min until 0.17 min, combined with a sample injection speed of 1.5 mL/min. Purge flow was set to 3 mL/min from 0.17 min to 2.17 min. Injection temperature was held at 40 °C for 0.1 min followed by ramping at 12 °C/sec until 320 °C, which was held for 2 min. Column flow was set to 7.5 mL, which was held constant throughout the GC program. The GC program was set to hold at 60 °C for 1 min, ramp 30 °C/min to 220 °C, ramp 2 °C/min to 250 °C and a final ramp of 30 °C/min to 220 °C, which was held for 2 min. Temperature of the transfer line from GC to PFC and the PFC itself was set to 250 °C. The PFC was customized to collect the peaks of **2**, **3b**, **3c**, **5d** and **7h**, and **10b** by their retention time identified by the MS. The MS for monitoring the PFC purification was set in scan mode from *m/z* 35 to *m/z* 500, with a threshold of 150 ion counts. Solvent cut-off was set to 4 min and the temperature of the MS source and the MS quadropole - to 300 °C and 150 °C, respectively.

Large scale biosynthesis in *S. cerevisiae* and isolation of 9-hydroxy-13*R*-manoyl oxide (**3a**) for NMR analysis

For biosynthesis of **3a** in amounts sufficient for NMR analysis, the *S. cerevisiae* strain EFSC4494 carrying chromosomally integrated *CYP76AH16* was inoculated into a pre-culture of 5 mL selective media (SC-Ura) and grown for 16 h at 30 °C and 400 rpm. A 1 mL aliquot of the pre-culture was used for inoculation of 100 mL non-selective media (SC) and grown in a 500 mL Erlenmeyer shake-flask for 120 h at 30 °C with horizontal shaking at 180 rpm. Following addition of 100 mL UV-grade 99.9% ethanol and maintenance of the sample at 60 °C for 20 min, 200 mL of *n*-hexane was added and the sample shaken for 2 h at room temperature. The hexane phase was concentrated by rotor evaporation and subjected to column chromatography (dual layer Florisil/Na₂SO₄ 6mL PP SPE TUBE, Supelco Analytical) with a gradient composed of *n*-hexane and 1-15% ethyl acetate.

580

581 Metabolic engineering of *S. cerevisiae* for the production of forskolin

582 All genes selected for functional expression in *S. cerevisiae* were codon optimized for efficient
583 expression in *S. cerevisiae*, and purchased as DNA STRINGS (Geneart, LifeTechnologies). Genomic
584 integration was chosen over expression via episomal plasmids to favor simultaneous expression of
585 a number of genes as well as to enable the use of selection marker recycling (**Jensen et al., 2014**).
586 The 13R-manoyl oxide producing *S. cerevisiae* strain EFSC4498 (**Andersen-Ranberg et al., 2016**)
587 was used to test all the selected gene combinations for their ability of affording synthesis of
588 forskolin and intermediate products. All genes were cloned into yeast genome integration
589 plasmids by the USER technique (**Nour-Eldin et al., 2010**) targeting incorporation into site XI-2
590 (**Mikkelsen et al., 2012**). Transformants were verified by PCR on genomic DNA for correct insertion
591 of heterologous genes and grown and tested in 96 deep-well plates (**Andersen-Ranberg et al.,**
592 **2016**). The yeast strain found to produce the highest amount of forskolin and which exhibited
593 stability through several cultivation rounds (EVST21543) was selected for cultivation for 140 h in a
594 5 L fermenter using minimal medium and glucose limited conditions. Forskolin production was
595 monitored using withdrawn culture aliquots. Forskolin was extracted from the mixture of yeast
596 cells and culture broth using 85% methanol and incubation for 20 min at 75 °C and the extract
597 centrifuged (10000 g for 5 min) to precipitate yeast debris. The supernatant obtained was used
598 after filtration for LC-MS analysis and forskolin quantification.

599

600 Forskolin quantification synthesized from yeast strain EVST21543 growing in the fermenter and
601 comparison to *C. forskohlii* root extract

For forskolin quantification, aliquots of the yeast samples (with broth) collected at specific time points (**Figure 3**) were combined with methanol to give a concentration of 85% methanol, incubated at 75 °C for 20 min, filtered and then analyzed by LC-MS. Quantification was based on a standard calibration curve of forskolin purchased from Sigma-Aldrich. An Ultimate 3000 UHPLC⁺ Focused system (Dionex Corporation, Sunnyvale, CA, USA) coupled to a Bruker Compact ESI-QTOF-MS (Bruker Daltonik, Bremen, Germany) was used to quantify forskolin. Samples were separated on a Kinetex XB-C18 column (100 × 2.1 mm i.d., 1.7 µm particle size, 100 Å pore size; Phenomenex Inc., Torrance, CA, USA) maintained at 40°C with a flow rate of 0.3 mL/min and mobile phase consisting of 0.05% (v/v) formic acid in water (solvent A) and 0.05% (v/v) formic acid in acetonitrile (solvent B). The gradient LC method used for quantification was as follows: solvent B was held at 20% for 30 s, then ramped to 100% over 8.5 min, held at 100% for 2 min, decreased to 20% over 30 s and held for 3.5 min to give an overall run time of 15 min. The ESI source parameters were as follows: capillary voltage, 4500 V; nebulizer pressure 1.2 bar; dry gas flow, 8 l/min; dry gas temperature, 250°C. The QTOF-MS was operated in MS only mode with collision cell energy of 7 eV and collision cell RF of 500 Vpp. Ions were monitored in the positive mode over a range of 50-1300 *m/z* and spectra collected at a rate of 2 Hz. For comparison of yeast profiles to *C. forskohlii* root extract, roots were grinded and then extracted with 85% methanol, incubated at 75 °C for 30 min, filtered and analyzed by LC-MS. Analysis was performed as described for forskolin quantification but with the following gradient method: 20 % B for 1 min, increased to 100 % B over 22 min and then returned to 20% B in 0.5 min and held for 4 min.

Quantification of 13*R*-manoyl oxide (**1**) and 9-hydroxy-13*R*-manoyl oxide (**3a**) synthesized from yeast strain EVST21543 growing in the fermenter

Yeast samples were collected at specific time points (**Figure 10**) and samples kept at -20°C in glass vials. For diterpenoid extraction, 500 μL of *n*-hexane was added to 500 μL yeast broth, shaken for 1 h at room temperature and separated into two phases by centrifugation at 2500 rpm and stored overnight at 4°C . The hexane phase was then diluted 10 times and run on a SCION 436 GC-FID (Bruker). Sample (1 μL) was injected in splitless mode at 280°C . The GC-program was as follows: 60°C for 1 min, ramp at $20^{\circ}\text{C}/\text{min}$ to 160°C , ramp at $10^{\circ}\text{C}/\text{min}$ from 160 to 240°C , ramp at $20^{\circ}\text{C}/\text{min}$ from 240 to 320°C , hold at 320°C for 2 min. H_2 was used as carrier gas with a linear flow of 50 mL/min. The FID was set at 300°C , with N_2 flow of 25 mL/min, H_2 at 30 mL/min and air at 300 mL/min. Data sampling rate was 10 Hz. Compound **1** and **3a** was identified by comparing the retention time with an authentic standard and quantification was based on FID peak area and a standard curve of **1**.

NMR analysis

All NMR experiments were recorded at 300 K in CDCl_3 using a Bruker Avance III 600 MHz NMR spectrometer (^1H operating frequency 600.13 MHz) equipped with a Bruker SampleJet sample changer and a cryogenically cooled gradient inverse triple-resonance 1.7-mm TCI probe-head (Bruker Biospin, Rheinstetten, Germany). The experiments were acquired in automation (temperature equilibration to 300 K, optimization of lock parameters, gradient shimming, and setting of receiver gain). Both one-dimensional ^1H and ^{13}C spectra were acquired with 30° -pulses and 64k data points. The ^1H spectra were recorded with 3.66 s inter-pulse intervals and the FID was multiplied with an exponential function corresponding to line-broadening of 0.3 Hz prior to Fourier transform. An acquisition time of 0.9 s were used for the ^{13}C experiments with an additional relaxation delay of 2.0 s. Protons were decoupled during acquisition using waltz16

648 composite pulse sequence. Backward linear prediction was used to correct the first complex data
649 points of ^{13}C FIDs before zero-filling to 128k data points and application of exponential window
650 function with a line-broadening factor of 1.0 Hz. Two-dimensional homo- and heteronuclear
651 experiments were acquired with 2048 data points in the direct dimension and 128 (DQF-COSY and
652 HMBC) or 256 (multiplicity edited HSQC and phase sensitive NOESY) data points in the indirect
653 dimension; with spectral widths optimized from the corresponding ^1H spectra. The HMBC and
654 HSQC experiments were optimized for $^nJ_{\text{H,C}} = 10$ Hz and $^1J_{\text{H,C}} = 145$ Hz, respectively. Acquisition and
655 processing of NMR data were performed using Topspin ver. 3.0 (Bruker Biospin GmbH), and
656 IconNMR ver. 4.2 (Bruker Biospin GmbH) was used for controlling automated sample change and
657 acquisition.

658
659 **Acknowledgements:** We thank Dr. Sotirios Kampranis for providing ferruginol and 11β -hydroxy-
660 $13R$ -manoyl oxide reference compounds and Dr. Angelos Kanellis for providing RoFS1 and SfFS
661 cDNAs. This work was supported by the VILLUM research center "Plant Plasticity" (B.L.M.), the
662 Center for Synthetic Biology "bioSYNergy" supported by the UCPH Excellence Program for
663 Interdisciplinary Research (B.L.M.), the Novo Nordisk Foundation (Bj.H.), an ERC Advanced Grant
664 to BLM (ERC-2012-ADG_20120314), individual Marie Skłodowska-Curie fellowships to I.P. and
665 A.M.H. Bj.H is in part supported by the DOE Great Lakes Bioenergy Research Center (DOE Office of
666 Science BER DE-FC02-07ER64494) and gratefully acknowledges the Strategic Partnership Grant
667 (15-SPG-Full-3101), MSU Foundation, startup funding from the Department of Molecular Biology
668 and Biochemistry, Michigan State University and support from Michigan State University
669 AgBioResearch (MICL02454).

670

671 **Competing interests:** J.A-R., N.B.J., I.P., B.L.M. and Bj.H. have filed international patent

672 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds'.

673 N.B.J. and J.H. are employees of Evolva SA

674

675 References

- 676 Alasbahi R, Melzig M. 2010a. Plectranthus barbatus: a review of phytochemistry, ethnobotanical uses and
677 pharmacology - Part 1. *Planta Medica* **76**: 653-661.
- 678 Alasbahi R, Melzig M. 2010b. Plectranthus barbatus: a review of phytochemistry, ethnobotanical uses and
679 pharmacology - part 2. *Planta Medica* **76**: 753-765.
- 680 Andersen-Ranberg J, Kongstad KT, Nielsen MT, Jensen NB, Pateraki I, Bach SS, Hamberger B, Zerbe P, Staerk
681 D, Bohlmann J, Møller BL, Hamberger B. 2016. Expanding the landscape of diterpene structural diversity
682 through stereochemically controlled combinatorial biosynthesis. *Angewandte Chemie International Edition*
683 **55**: 2142-2146.
- 684 Appendino G. 2014. Omnia praeclara rara. The quest for ingenol heats up. *Angewandte Chemie*
685 *International Edition* **53**: 927-929.
- 686 Asada Y, Li W, Terada T, Kuang X, Li Q, Yoshikawa T, Hamaguchi S, Namekata I, Tanaka H, Koike K. 2012.
687 Labdane-type diterpenoids from hairy root cultures of *Coleus forskohlii*, possible intermediates in the
688 biosynthesis of forskolin. *Phytochemistry* **79**: 141-146.
- 689 Biggs BW, Lim CG, Sagliani K, Shankar S, Stephanopoulos G, De Mey M, Ajikumar PK. 2016. Overcoming
690 heterologous protein interdependency to optimize P450-mediated Taxol precursor synthesis in *Escherichia*
691 *coli*. *Proceedings of the National Academy of Sciences of the United States of America* **113**: 3209-3214.
- 692 Bozic D, Papaefthimiou D, Bruckner K, Vos RC, Tsoleridis CA, Katsarou D, Papanikolaou A, Pateraki I,
693 Chatzopoulou FM, Dimitriadou E. 2015. Towards elucidating carnosic acid biosynthesis in Lamiaceae:
694 functional characterization of the three first steps of the pathway in *Salvia fruticosa* and *Rosmarinus*
695 *officinalis*. *PLoS ONE* **10**:
- 696 Božić D, Papaefthimiou D, Brückner K, de Vos RCH, Tsoleridis CA, Katsarou D, Papanikolaou A, Pateraki I,
697 Chatzopoulou FM, Dimitriadou E, Kostas S, Manzano D, Scheler U, Ferrer A, Tissier A, Makris AM, Kampranis
698 SC, Kanellis AK. 2015. Towards elucidating carnosic acid biosynthesis in Lamiaceae: Functional
699 characterization of the three first steps of the pathway in *Salvia fruticosa* and *Rosmarinus officinalis*. *PLoS*
700 *ONE* **10**: e0124106.
- 701 Brochado AR, Matos C, Møller BL, Hansen J, Mortensen UH, Patil KR. 2010. Improved vanillin production in
702 baker's yeast through in silico design. *Microbial Cell Factories* **9**: 1-15.
- 703 Brown S, Clastre M, Courdavault V, O'Connor SE. 2015. De novo production of the plant-derived alkaloid
704 strictosidine in yeast. *Proceedings of the National Academy of Sciences of the United States of America* **112**:
705 3205-3210.
- 706 Cragg GM, Newman DJ. 2013. Natural products: A continuing source of novel drug leads. *Biochimica et*
707 *Biophysica Acta (BBA) - General Subjects* **1830**: 3670-3695.
- 708 D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura
709 EK, Ito S, Fisher DE. 2006. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-
710 induced tanning. *Nature* **443**: 340-344.
- 711 D'Auria JC. 2006. Acyltransferases in plants: a good time to be BAHD. *Current Opinion in Plant Biology* **9**:
712 331-340.
- 713 David B, Wolfender J-L, Dias D. 2015. The pharmaceutical industry and natural products: historical status
714 and new trends. *Phytochemistry Reviews* **14**: 299-315.
- 715 Doseyici S, Mehmetoglu I, Toker A, Yerlikaya F, Erbay E. 2014. The effects of forskolin and rolipram on
716 cAMP, cGMP and free fatty acid levels in diet induced obesity. *Biotechnic & Histochemistry* **89**: 388-392.
- 717 Englund E, Andersen-Ranberg J, Miao R, Hamberger B, Lindberg P. 2015. Metabolic engineering of
718 *Synechocystis* sp. PCC 6803 for production of the plant diterpenoid manoyl oxide. *ACS Synthetic Biology* **4**:
- 719 Gabetta B, Zini G, Danieli B. 1989. Minor diterpenoids of *Coleus forskohlii*. *Phytochemistry* **28**: 859-862.
- 720 Galanie S, Thodey K, Trenchard IJ, Filsinger Interrante M, Smolke CD. 2015. Complete biosynthesis of
721 opioids in yeast. *Science* **349**: 1095-1100.

722 Godard MP, Johnson BA, Richmond SR. 2005. Body composition and hormonal adaptations associated with
723 forskolin consumption in overweight and obese men. *Obes Res* **13**: 1335-1343.

724 Graham IA, Besser K, Blumer S, Branigan CA, Czechowski T, Elias L, Guterman I, Harvey D, Isaac PG, Khan
725 AM, Larson TR, Li Y, Pawson T, Penfield T, Rae AM, Rathbone DA, Reid S, Ross J, Smallwood MF, Segura V,
726 Townsend T, Vyas D, Winzer T, Bowles D. 2010. The Genetic Map of *Artemisia annua* L. Identifies Loci
727 Affecting Yield of the Antimalarial Drug Artemisinin. *Science* **327**: 328-331.

728 Guo J, Ma X, Cai Y, Ma Y, Zhan Z, Zhou YJ, Liu W, Guan M, Yang J, Cui G, Kang L, Yang L, Shen Y, Tang J, Lin H,
729 Ma X, Jin B, Liu Z, Peters RJ, Zhao ZK, Huang L. 2015. Cytochrome P450 promiscuity leads to a bifurcating
730 biosynthetic pathway for tanshinones. *New Phytologist* **210**: 525–534.

731 Guo J, Zhou YJ, Hillwig ML, Shen Y, Yang L, Wang Y, Zhang X, Liu W, Peters RJ, Chen X, Zhao ZK, Huang L.
732 2013. CYP76AH1 catalyzes turnover of miltiradiene in tanshinones biosynthesis and enables heterologous
733 production of ferruginol in yeasts. *Proceedings of the National Academy of Sciences of the United States of*
734 *America* **110**: 12108-12113.

735 Hansen EH, Møller BL, Kock GR, Bünner CM, Kristensen C, Jensen OR, Okkels FT, Olsen CE, Motawia MS,
736 Hansen J. 2009. De Novo Biosynthesis of Vanillin in Fission Yeast (*Schizosaccharomyces pombe*) and Baker's
737 Yeast (*Saccharomyces cerevisiae*). *Applied and Environmental Microbiology* **75**: 2765-2774.

738 Hardy K, Buckley S, Collins M, Estalrich A, Brothwell D, Copeland L, García-Tabernero A, García-Vargas S, de
739 la Rasilla M, Lalueza-Fox C, Huguet R, Bastir M, Santamaría D, Madella M, Wilson J, Cortés Á, Rosas A. 2012.
740 Neanderthal medics? Evidence for food, cooking, and medicinal plants entrapped in dental calculus.
741 *Naturwissenschaften* **99**: 617-626.

742 Ignea C, Athanasakoglou A, Ioannou E, Georgantea P, Triikka FA, Loupassaki S, Roussis V, Makris AM,
743 Kampranis SC. 2016a. Carnosic acid biosynthesis elucidated by a synthetic biology platform. *Proceedings of*
744 *the National Academy of Sciences of the United States of America* **113**: 3681-3686.

745 Ignea C, Ioannou E, Georgantea P, Triikka FA, Athanasakoglou A, Loupassaki S, Roussis V, Makris AM,
746 Kampranis SC. 2016b. Production of the forskolin precursor 11 β -hydroxy-manoyl oxide in yeast using
747 surrogate enzymatic activities. *Microbial Cell Factories* **15**: 1-11.

748 Jeandet P, Delaunois B, Aziz A, Donnez D, Vasserot Y, Cordelier S, Courot E. 2012. Metabolic engineering of
749 yeast and plants for the production of the biologically active hydroxystilbene, resveratrol. *Journal of*
750 *Biomedical Biotechnololy* **2012**:

751 Jensen NB, Strucko T, Kildegaard KR, David F, Maury J, Mortensen UH, Forster J, Nielsen J, Borodina I. 2014.
752 EasyClone: method for iterative chromosomal integration of multiple genes *Saccharomyces cerevisiae*.
753 *FEMS Yeast Res* **14**: 238-248.

754 Jia M, Potter KC, Peters RJ. 2016. Extreme promiscuity of a bacterial and a plant diterpene synthase enables
755 combinatorial biosynthesis. *Metabolic Engineering* **37**: 24-34.

756 Jung ST, Lauchli R, Arnold FH. 2011. Cytochrome P450: taming a wild type enzyme. *Current Opinion in*
757 *Biotechnology* **22**: 809-817.

758 Kampranis SC, Makris AM. 2012. Developing a yeast cell factory for the production of terpenoids.
759 *Computational and Structural Biotechnology Journal* **3**: e201210006.

760 Kavitha C, Rajamani K, Vadivel E. 2010. *Coleus forskohlii* – A comprehensive review on morphology,
761 phytochemistry and pharmacological aspects. *Journal of Medicinal Plants Research* **4**: 278-285.

762 Kawamura S, Chu H, Felding J, Baran PS. 2016. Nineteen-step total synthesis of (+)-phorbol. *Nature* **532**: 90-
763 93.

764 Kikura M, Morita K, Sato S. 2004. Pharmacokinetics and a simulation model of colforsin daropate, new
765 forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting.
766 *Pharmacological Research* **49**: 275-281.

767 King AJ, Brown GD, Gilday AD, Forestier E, Larson TR, Graham IA. 2016. A Cytochrome P450-Mediated
768 Intramolecular Carbon–Carbon Ring Closure in the Biosynthesis of Multidrug-Resistance-Reversing
769 Lathyrane Diterpenoids. *ChemBioChem* **17**: 1593-1597.

770 Kosley RW, Cherill RJ. 1989. Regioselective acylations of 7-desacetylforskolin. *The Journal of Organic*
771 *Chemistry* **54**: 2972-2975.

772 Laursen T, Borch J, Knudsen C, Bavishi K, Torta F, Martens H, Silvestro D, Hatzakis N, Wenk M, Dafforn T,
 773 Olsen C, Motawia M, Hamberger B, Møller BL, Bassard J-E. 2016. Characterization of a dynamic metabolon
 774 producing the defense compound dhurrin in sorghum. *Science in press*:
 775 Li Y, Smolke CD. 2016. Engineering biosynthesis of the anticancer alkaloid noscapine in yeast. *Nat Commun*
 776 **7**: 12137.
 777 Liu T, Khosla C. 2010. A Balancing Act for Taxol Precursor Pathways in *E. coli*. *Science* **330**: 44-45.
 778 Luo D, Callari R, Hamberger B, Wubshet SG, Nielsen MT, Andersen-Ranberg J, Hallström BM, Cozzi F, Heider
 779 H, Lindberg Møller B, Staerk D, Hamberger B. 2016. Oxidation and cyclization of casbene in the biosynthesis
 780 of Euphorbia factors from mature seeds of Euphorbia lathyris L. *Proceedings of the National Academy of*
 781 *Sciences of the United States of America* **113**: E5082-E5089.
 782 Mikkelsen MD, Buron LD, Salomonsen B, Olsen CE, Hansen BG, Mortensen UH, Halkier BA. 2012. Microbial
 783 production of indolylglucosinolate through engineering of a multi-gene pathway in a versatile yeast
 784 expression platform. *Metabolic Engineering* **14**: 104-111.
 785 Mithöfer A, Boland W. 2012. Plant Defense Against Herbivores: Chemical Aspects. *Annual Review of Plant*
 786 *Biology* **63**: 431-450.
 787 Mora-Pale M, Sanchez-Rodriguez SP, Linhardt RJ, Dordick JS, Koffas MAG. 2014. Biochemical strategies for
 788 enhancing the in vivo production of natural products with pharmaceutical potential. *Current Opinion in*
 789 *Biotechnology* **25**: 86-94.
 790 Nakagawa A, Matsumura E, Koyanagi T, Katayama T, Kawano N, Yoshimatsu K, Yamamoto K, Kumagai H,
 791 Sato F, Minami H. 2016. Total biosynthesis of opiates by stepwise fermentation using engineered
 792 *Escherichia coli*. *Nat Commun* **7**:10390:
 793 Nelson D, Werck-Reichhart D. 2011. A P450-centric view of plant evolution. *The Plant Journal* **66**: 194-211.
 794 Nelson DR. 2009. The Cytochrome P450 Homepage. *Human Genomics* **4**: 59-65.
 795 Nelson DR. 2013. A world of cytochrome P450s. *Philosophical Transactions of the Royal Society B: Biological*
 796 *Sciences* **368**:
 797 Nielsen MT, Ranberg JA, Christensen U, Christensen HB, Harrison SJ, Olsen CE, Hamberger B, Møller BL,
 798 Nørholm MHH. 2014. Microbial Synthesis of the Forskolin Precursor Manoyl Oxide in an Enantiomerically
 799 Pure Form. *Applied and Environmental Microbiology* **80**: 7258-7265.
 800 Nour-Eldin H, Geu-Flores F, Halkier B (2010). USER Cloning and USER Fusion: The Ideal Cloning Techniques
 801 for Small and Big Laboratories. *Plant Secondary Metabolism Engineering*. AG Fett-Neto, Humana Press. **643**:
 802 185-200.
 803 Nour-Eldin HH, Hansen BG, Nørholm MHH, Jensen JK, Halkier BA. 2006. Advancing uracil-excision based
 804 cloning towards an ideal technique for cloning PCR fragments. *Nucleic Acids Research* **34**: e122.
 805 Ondari ME, Walker KD. 2008. The Taxol Pathway 10-O-Acetyltransferase Shows Regioselective Promiscuity
 806 with the Oxetane Hydroxyl of 4-Deacetyltaxanes. *Journal of the American Chemical Society* **130**: 17187-
 807 17194.
 808 Paddon CJ, Keasling JD. 2014. Semi-synthetic artemisinin: a model for the use of synthetic biology in
 809 pharmaceutical development. *Nature Reviews in Microbiology* **12**: 355-367.
 810 Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell MD, Tai A, Main A, Eng D. 2013.
 811 High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature* **496**:
 812 Pateraki I, Andersen-Ranberg J, Hamberger B, Heskes AM, Martens HJ, Zerbe P, Bach SS, Møller BL,
 813 Bohlmann J, Hamberger B. 2014. Manoyl oxide (13R), the biosynthetic precursor of forskolin, is synthesized
 814 in specialized root cork cells in *Coleus forskohlii*. *Plant Physiology* **164**: 1222-1236.
 815 Pateraki I, Heskes AM, Hamberger B (2015). Cytochromes P450 for Terpene Functionalisation and
 816 Metabolic Engineering. *Biotechnology of Isoprenoids*. J Schrader, J Bohlmann. Cham, Springer International
 817 Publishing, 10.1007/10_2014_301: 107-139.
 818 Peplow M. 2016. Synthetic biology's first malaria drug meets market resistance. *Nature* **530**: 389-390.
 819 Renault H, Bassard J-E, Hamberger B, Werck-Reichhart D. 2014. Cytochrome P450-mediated metabolic
 820 engineering: current progress and future challenges. *Current Opinion in Plant Biology* **19**: 27-34.

Roberts SC. 2007. Production and engineering of terpenoids in plant cell culture. *Nature Chemical Biology* **3**: 387-395.

Schwarz R, Dayhoff M. 1979. Matrices for detecting distant relationships. *Atlas of protein sequences*, National Biomedical Research Foundation.

Seamon KB, Padgett W, Daly JW. 1981. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. *Proceedings of the National Academy of Sciences of the United States of America* **78**: 3363-3367.

Spanner SB, Bassard J-É, Andersen-Ranberg J, Møldrup ME, Simonsen HT, Hamberger B. 2014. High throughput testing of terpenoid biosynthesis candidate genes using transient expression in *Nicotiana benthamiana*. *Methods in Molecular Biology*, Humana Press.

Srivastava S, Misra A, Mishra P, Shukla P, Kumar M, Sundaresan V, Negi KS, Agrawal PK, Singh Rawat AK. 2017. Molecular and chemotypic variability of forskolin in *Coleus forskohlii* Briq., a high value industrial crop collected from Western Himalayas (India). *RSC Advances* **7**: 8843-8851.

Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Molecular Biology and Evolution* **30**: 2725-2729.

Toya Y, Schwencke C, Ishikawa Y. 1998. Forskolin Derivatives with Increased Selectivity for Cardiac Adenylyl Cyclase. *Journal of Molecular and Cellular Cardiology* **30**: 97-108.

Tuominen L, Johnson V, Tsai C-J. 2011. Differential phylogenetic expansions in BAHD acyltransferases across five angiosperm taxa and evidence of divergent expression among *Populus* paralogs. *BMC Genomics* **12**: 236.

Vazquez-Albacete D, Cavaleiro AM, Christensen U, Seppälä S, Møller BL, Nørholm MHH. 2016. An expression tag toolbox for microbial production of membrane bound plant cytochromes P450. *Biotechnology and Bioengineering*, 10.1002/bit.26203 in press.

Wagh VD, Patil PN, Surana SJ, Wagh KV. 2012. Forskolin: Upcoming antiglaucoma molecule. *Journal of Postgraduate Medicine* **58**: 199-202.

Walker K, Croteau R. 2000. Molecular cloning of a 10-deacetylbaicatin III-10-O-acetyl transferase cDNA from *Taxus* and functional expression in *Escherichia coli*. *Proceedings of the National Academy of Sciences of the United States of America* **97**: 583-587.

Werck-Reichhart D, Feyereisen R. 2000. Cytochromes P450: a success story. *Genome Biology* **1**: reviews 3003.3001.

Woldemariam MG, Baldwin IT, Galis I. 2011. Transcriptional regulation of plant inducible defenses against herbivores: a mini-review. *Journal of Plant Interactions* **6**: 113-119.

Ye H, Deng G, Liu J, Qiu FG. 2009. Expedient Construction of the Ziegler Intermediate Useful for the Synthesis of Forskolin via Consecutive Rearrangements. *Organic Letters* **11**: 5442-5444.

Yoneyama M, Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Hashimoto K. 2002. Cardiovascular and Adenylyl Cyclase Stimulating Effects of Colforsin Daropate, a Water-Soluble Forskolin Derivative, Compared With Those of Isoproterenol, Dopamine and Dobutamine. *Circulation Journal* **66**: 1150-1154.

Yuan C, Jin Y, Wilde NC, Baran PS. 2016. Short, Enantioselective Total Synthesis of Highly Oxidized Taxanes. *Angewandte Chemie International Edition* **55**: 8280-8284.

Zerbe P, Hamberger B, Yuen MMS, Chiang A, Sandhu HK, Madilao LM, Nghuen A, Hamberger B, Spanner Bach S, Bohlmann J. 2013. Gene discovery of modular diterpene metabolism in non-model systems. *Plant Physiology*, 10.1104/pp.113.218347

Zhang WW, Luo JG, Wang JS, Lu YY, Kong LY. 2009. LC-DAD-ESI-MS-MS for characterization and quantitative analysis of diterpenoids from *Coleus forskohlii*. *Chromatographia* **70**: 1635-1643.

Zhou K, Qiao K, Edgar S, Stephanopoulos G. 2015. Distributing a metabolic pathway among a microbial consortium enhances production of natural products. *Nature Biotechnology* **33**: 377-383.

Zi J, Peters RJ. 2013. Characterization of CYP76AH4 clarifies phenolic diterpenoid biosynthesis in the Lamiaceae. *Organic and Biomolecular Chemistry* **11**: 7650-7652.

Figures




Figure 1. Biosynthesis of forskolin in the root cork cells of *C. forskohlii*. **(A)** Scheme showing the structures of the diterpene precursor 13R-manoyl oxide, deacetylforskolin and forskolin on a background of root cork cells with forskolin containing oil bodies. **(B)** Transcript profiles of biosynthetic candidate genes in selected tissues of *C. forskohlii* as shown on the illustrations.




Figure 2. 13R-manoyl oxide oxide-derived hydroxylated products formed following transient expression of *Cf*CYP76AHs in *N. benthamiana*. (A) Molecular formulas of the hydroxylated products obtained using different *Cf*CYP76AHs. The number of hydroxylations of each compound was deduced from its accurate molecular mass (<5ppm, **Table 3**) as determined by LC-qTOF-MS or NMR. Each different compound is marked by a number. (B) Chemical structures of the compounds marked with numbers in bold in A as determined by NMR (**Table 1 and 2**).





Figure 3. GC-MS analysis of 13R-manoyl oxide (1) derived diterpenoids obtained by transient expression of CYP76AHs from *C. forskohlii* in *N. benthamiana*. **(A)** GC-MS total ion chromatograms (TIC) of extracts from *N. benthamiana* transiently expressing *CfCXS*, *CfGGPPS*, *CfTPS2* and *CfTPS3* (13R-manoyl oxide biosynthesis) genes in combination with water (-), *CfCYP76AH15*, *CfCYP76AH17*, *CfCYP76AH8*, *CfCYP76AH11* or *CfCYP76AH16*. 1-eicosene was used as internal standard (IS). 13R-manoyl oxide (1) was identified only in (-), indicating that it is further metabolized by the *CfCYP76AH15*, *CfCYP76AH17*, *CfCYP76AH8*, *CfCYP76AH11* and *CfCYP76AH16* enzymes. **(B)** m/z spectrum of 11-oxo-13R-manoyl oxide (2). **(C)** m/z spectrum of 9-hydroxy-13R-manoyl oxide (3a). The structure of both compounds was verified by NMR analysis (**Table 1 and 2**). The compounds have been identified previously in *C. forskohlii* as putative intermediates in the *in planta* biosynthesis of forskolin (Asada *et al.*, 2012). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and representative chromatograms are shown.



908

909

910 **Figure 3-Figure Supplement 1.** LC-qTOF-MS analysis of 13R-manoyl oxide-derived diterpenoids
911 obtained by transient expression of *C. forskohlii* CYP76AH encoding genes in *N. benthamiana*.
912 Total ion chromatograms (TIC) of extracts expressing the 13R-manoyl oxide biosynthesis genes
913 (*CfCXS*, *CfGGPPS*, *CfTPS2*, *CfTPS3*) in combination with water (-), *CfCYP76AH8*, *CfCYP76AH17*,
914 *CfCYP76AH15*, *CfCYP76AH11* or *CfCYP76AH16* are shown. 13R-manoyl oxide-derived oxygenated
915 compounds formed (marked with grey bars) and their identity including their molecular formulas
916 was confirmed by their accurate mass (5 ppm tolerance, **Table 3**). The identity of 1,11-dihydroxy-
917 13R-manoyl oxide (**5d**) and 9-deoxydeactylforskolin (**10b**) was confirmed by NMR analysis (**Figure**
918 **4 and Table 1 and 2**). No 13R-manoyl oxide-derived diterpenoids were detected in the water
919 control (-). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and
920 representative chromatograms are shown.

921




Figure 3-Figure Supplement 2. GC-MS analysis of 13R-manoyl oxide-derived diterpenoids following transient expression in *N. benthamiana* of the *C. forskohlii* gene encoding CfCYP71D281 together with genes encoding the required enzymes for biosynthesis of 13R-manoyl oxide (CfCXS, CfGGPPS, CfTPS2, CfTPS3). A: GC-MS total ion chromatograms (TIC) of extracts from *N. benthamiana* transiently expressing 13R-manoyl oxide biosynthesis genes in combination with water (-) or CfCYP71D381, respectively. 1-eicosene was used as internal standard (IS) and 13R-manoyl oxide (**1**) was identified in both (-) and the CfCYP71D381 samples. Compounds **3b** and **3c** were identified in extracts from *N. benthamiana* expressing CfCYP71D381 together with the genes in 13R-manoyl oxide biosynthesis. CfCYP71D381 efficiently converted **1** to a mixture of two monohydroxylated 13R-manoyl oxide derivatives (**3b** and **3c**). Structural elucidation by NMR (**Figure 4 and Table 1 and 2**) showed hydroxylation of **1** at positions C-2 (**3b**) and C-19 (**3c**). These hydroxylation positions do not coincide with those found in forskolin and to our knowledge have not been observed in other diterpenoids known from *C. forskohlii*. B: *m/z* spectrum of 2-hydroxy-13R-manoyl oxide (**3b**). C: *m/z* spectrum of 19-hydroxy-13R-manoyl oxide (**3c**). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and representative chromatograms are shown.






A Molecule structures confirmed by authentic standard(s)**B** Molecule structures confirmed by comparison of ^{13}C chemical shift with reference values**C** Molecule structures obtained by ^1H , ^{13}C , HMBC, and NOESY measurements

Figure 4. Structures of key compounds presented in this work. A: compounds confirmed using authentic standards. B: compounds which structure was confirmed/identified by comparison of ^{13}C NMR data with existing literature. C: compounds which structure was confirmed/identified by HMBC and NOE correlations for assigning position of OH-groups (marked in red), whereas couplings identified in the previously uncharacterized compounds **3b**, **3c** and **5d** are marked in black. All other molecular structures were confirmed by ^{13}C chemical shifts in comparisons to reference values (**Table 1**, **Figure 4-source data 1**).



957 **Figure 5.** LC-qTOF-MS analysis of 13*R*-manoyl oxide-derived diterpenoids obtained by transient
958 expression of combinations of *C. forskohlii* CYP encoding genes, together with genes encoding the
959 required enzymes for biosynthesis of 13*R*-manoyl oxide in *N. benthamiana*. Total ion
960 chromatograms (TIC) of extracts expressing the 13*R*-manoyl oxide biosynthesis genes (*CfCXS*,
961 *CfGGPPS*, *CfTPS2*, *CfTPS3*), in combination with (from the top) water (-), *CfCYP76AH8* +
962 *CfCYP76AH11* + *CfCYP76AH16*, *CfCYP76AH17* + *CfCYP76AH11* + *CfCYP76AH16*, and *CfCYP76AH15* +
963 *CfCYP76AH11* + *CfCYP76AH16* are shown. Hydroxylated 13*R*-manoyl oxide-derived diterpenoids
964 (marked with grey bars) and their identity including their molecular formulas were confirmed by
965 accurate mass (5 ppm tolerance, **Table 3**). Compounds present in trace amounts are not marked.
966 The identity of 1,11-dihydroxy-13*R*-manoyl oxide (**5d**), 9-deoxydeacetylforskolin (**10b**) and 1,9-
967 dideoxydeacetylforskolin (**7h**) was confirmed by NMR analysis (**Figure 4 and Table 1 and 2**),
968 whereas the identity of deacetylforskolin (**13b**) was confirmed by comparison to an authentic
969 chemically synthesized standard. No 13*R*-manoyl oxide-derived diterpenoids were identified in the
970 water control (-). Extracts from leaves of three different *N. benthamiana* plants have been
971 analyzed and representative chromatograms are shown.



974

975 **Figure 5-Figure Supplement 1.** LC-qTOF-MS analysis of 13*R*-manoyl oxide-derived diterpenoids
976 obtained by transient expression of combinations of *C. forskohlii* CYP76AH encoding genes in *N.*
977 *benthamiana*. Total ion chromatograms (TIC) of extracts expressing the 13*R*-manoyl oxide
978 biosynthesis genes (*CfCXs*, *CfGGPPS*, *CfTPS2*, *CfTPS3*) in combination with (from the top) water (-),
979 *CfCYP76AH15* + *CfCYP76AH11*, *CfCYP76AH8* + *CfCYP76AH11*, *CfCYP76AH17* + *CfCYP76AH11*,
980 *CfCYP76AH15* + *CfCYP76AH16*, *CfCYP76AH8* + *CfCYP76AH16* and *CfCYP76AH17* + *CfCYP76AH16* are
981 shown. Oxygenated 13*R*-manoyl oxide-derived diterpenoids (marked with grey bars) and their
982 identity including their molecular formulas were confirmed by their accurate mass (5 ppm
983 tolerance, **Table 3**). Compounds present in trace amounts are not marked. The identity of 1,11-
984 dihydroxy-13*R*-manoyl oxide (**5d**), 9-deoxydeacetylforskolin (**10b**), 1,9-dideoxydeacetylforskolin
985 (**7h**) was confirmed by NMR analysis (**Figure 4 and Table 1 and 2**). No 13*R*-manoyl oxide-derived
986 diterpenoids were detected in the water control (-). Extracts from leaves of three different *N.*
987 *benthamiana* plants have been analyzed and representative chromatograms are shown.
988




Figure 6. GC-MS analysis of miltiradiene-derived diterpenoids obtained by transient expression of *CfCYP76AH15* in *N. benthamiana*. (A) Total ion chromatograms (TIC) of extracts transiently expressing *CfCXs*, *CfGGPPS*, *CfTPS1* and *CfTPS3* (miltiradiene biosynthesis genes) in combination with water (-) or *CfCYP76AH15*. Dehydroabietadiene (DE) and miltiradiene (MT) were observed in the (-) extract, whereas ferruginol was observed in extracts from tissue expressing the miltiradiene biosynthesis genes together with *CfCYP76AH15*. In root cork extracts ferruginol was detected together with dehydroabietadiene. Presence of ferruginol was confirmed by comparison to an authentic standard (Ignea et al., 2016a), while presence of miltiradiene (B) and dehydroabietadiene (C) were confirmed by comparison of *m/z* spectra with previously characterized compounds (Andersen-Ranberg et al., 2016). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and representative chromatograms are shown.





Figure 7. GC-MS analysis of 13*R*-manoyl oxide-derived diterpenoids obtained by transient expression of *CYP76AHs* in *N. benthamiana*. (A) Total ion chromatograms (TIC) of extracts transiently expressing *CfCXS*, *CfGGPPS*, *CfTPS2* and *CfTPS3* (13*R*-manoyl oxide biosynthesis genes) in combination with water (-), *CfCYP76AH15*, *RoCYP76AH4*, *RoFS1* and *SpFS* are shown. 13*R*-manoyl oxide was observed in the (-) extracts, while 11-oxo-13*R*-manoyl oxide (**2**) was observed in the *CfCYP76AH15*, *RoCYP76AH4*, *RoFS1* and *SfFS* extracts. 11-Hydroxy-13*R*-manoyl oxide (**3d**) is observed only in extracts expressing the *RoFS1* and *SfFS1* genes. Presence of 11-hydroxy-13*R*-manoyl oxide was verified by comparison to an authentic standard (*Ignea et al., 2016b*) while identification of 11-oxo-13*R*-manoyl oxide was confirmed by comparison of *m/z* spectra with a previously characterized compound (**2**). The results show *RoCYP76AH4* has an activity similar to *CfCYP76AH15*, able to convert efficiently and specifically 13*R*-manoyl oxide to **2**. *RoFS1*, as well as *SfFS*, can also convert 13*R*-manoyl oxide to **2** but they catalyze the synthesis of an additional product, 11-hydroxy-13*R*-manoyl oxide (**3d**). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and representative chromatograms are shown.


1022



1023

1024 **Figure 8.** *De novo* biosynthesis of forskolin by transient expression of *C. forskohlii* genes in *N.*
 1025 *benthamiana* as monitored by LC-MS based extracted ion chromatograms (EIC). To monitor both
 1026 deacetylforskolin (**13b**) and forskolin (**16c**), the EIC were selected as the sum of m/z 433.2 \pm 0.1
 1027 and m/z 391.2 \pm 0.1. Chromatograms represent LC-MS analysis of extracts from leaves expressing
 1028 the 13*R*-manoyl oxide biosynthesis genes (*CfDXS*, *CfGGPPS*, *CfTP2* and *CfTPS3*) in combination with
 1029 (from the top): water (-); *CfCYP76AH15*, *CfCYP76AH11* and *CfCYP76AH16*; *CfCYP76AH15*,
 1030 *CfCYP76AH11*, *CfCYP76AH16* and *CfACT1-6*; *CfCYP76AH15*, *CfCYP76AH11*, *CfCYP76AH16* and *CfACT1-8*,
 1031 shown together with authentic standards (deacetylforskolin and forskolin). From leaves expressing
 1032 *CfACT1-6* together with forskolin specific CYPs, forskolin (**16c**) was identified together with two
 1033 other acetylated compounds (e.g. **16a**, **16b**) with the same molecular mass (**Table 3**). When
 1034 *CfACT1-8* was expressed instead, a predominant accumulation of forskolin was observed, with a
 1035 drastic reduction of non-specific acetylated products.

1036




1038

1039 **Figure 9.** LC-qTOF-MS analysis of 13*R*-manoyl oxide-derived diterpenoids obtained by transient
 1040 expression of combinations of *C. forskohlii* CYP and ACT encoding genes in *N. benthamiana*. Total
 1041 ion chromatograms (TIC) from extracts expressing the 13*R*-manoyl oxide biosynthesis genes
 1042 (*CfCX5*, *CfGGPPS*, *CfTPS2*, *CfTPS3*) in combination with (from the top) water (-), *CfCYP76AH15* +
 1043 *CfCYP76AH11* + *CfCYP76AH16* + *CfACT1-6*, and *CfCYP76AH15* + *CfCYP76AH11* + *CfCYP76AH16* +
 1044 *CfACT1-8* are shown. Hydroxylated and acetylated 13*R*-manoyl oxide-derived diterpenoids
 1045 (marked with grey bars) and their identity, including their molecular formulas, was confirmed by
 1046 their accurate mass (5 ppm tolerance, **Table 3**). Compounds present in trace amounts are not
 1047 marked. The identity of deacetylforskolin (**13b**) and forskolin (**16c**) was confirmed by comparison
 1048 to authentic standards. No 13*R*-manoyl oxide-derived diterpenoids were detected in the water
 1049 control (-). Extracts from leaves of three different *N. benthamiana* plants have been analyzed and
 1050 representative chromatograms are shown.

1051

1052




1053

1054

1055 **Figure 10.** Forskolin production in *Saccharomyces cerevisiae* following stable genomic integration
 1056 of codon-optimized *C. forskohlii* genes. **(A)** Forskolin (16c) accumulation in a fermenter batch using
 1057 the EVST21543 strain (expressing *CfCYP76AH15*, *CfCYP76AH11*, *CfCYP76AH16* and *CfACT1-8*
 1058 encoding genes in the EFSC4498 *S. cerevisiae* strain, optimized for the production of 13R-manoyl
 1059 oxide (**Andersen-Ranberg et al., 2016**)). **(B)** 13R-manoyl oxide (1) accumulation in EVST21543
 1060 strain. **(C)** 9-hydroxy-13R-manoyl oxide (3a) accumulation in EVST21543 strain. **(D)** EVST21543 strain
 1061 biomass monitored during the fermentation process. **(E)** The biosynthetic pathway used for the
 1062 production of forskolin in yeast. The fermentation event occurred once, and a triplicate of samples
 1063 have been analysed from each time course.

1064

1065




1066

1067

1068 **Figure 10-Figure Supplement 1.** Comparison of metabolite profiles between fermenter grown
 1069 yeast culture of the EVST21543 strain and *C. forskohlii* root extract analyzed by LC-MS. Forskolin
 1070 (**16c**) and 13R-manoyl oxide (**1**) were identified based on co-elution with standards and 9-hydroxy-
 1071 13R-manoyl oxide (**3a**) was identified based on the presence of the $[M+Na]^+$ ion, 329.2457
 1072 ($C_{20}H_{34}O_2Na^+$, Δ 0.7 ppm).

1073



1075

1076

Figure 11. Phylogeny of known full-length CYP76AHs. The enzymes used are listed below with their accession numbers or source of publication: CfCYP76AH15, KT382358; CfCYP76AH17, KT382360; CfCYP76AH8, KT382348; CfCYP76AH11, KT382349; CfCYP76AH16, KT382359; CfCYP76AH9, KT382347; CfCYP76AH10, KT382346; CfCYP71D381, KT382342; RoFS1, AJQ30187 (Božić *et al.*, 2015); SmCYP76AH3, KR140168 (Guo *et al.*, 2015); RoFS2, AJQ30188 (Božić *et al.*, 2015); SfFS, AJQ30186 (Božić *et al.*, 2015); RoCYP76AH4, (Zi *et al.*, 2013); RoCYP76AH5v1, (Zi *et al.*, 2013); RoCYP76AH5v2, (Zi *et al.*, 2013); RoCYP76AH6, (Zi *et al.*, 2013); RoCYP76AH7, (Zi *et al.*, 2013); SmCYP76AH1, AGN04215 (Guo *et al.*, 2013); SpCYP76AH24, ALM25796 (Ignea *et al.*, 2016a). *Coleus forskohlii* enzymes are indicated by a solid black triangle. CfCYP71D381 was chosen as a root because it can accept 13R-manoyl oxide as a substrate, but does not catalyze the synthesis of forskolin-related products. The number subscripts indicated at each enzyme refer to their respective enzymatic products, the structures of which are given on the right. Only the main products of each enzymes are mentioned. MO stands for manoyl oxide.

1090




Figure 12. Phylogenetic tree of *CfACT* encoding candidate genes together with BAHD family acyltransferase representatives from all clades according to D'Auria (2006). Accession numbers of the non-*Coleus forskohlii* selected protein sequences are shown next to the tree taxon names, while *C. forskohlii* peptide accession numbers are provided in **Figure 1-source data 1**. The analysis only includes functionally characterized members. *Coleus forskohlii* enzymes are indicated by a solid black triangle. The majority of the selected *CfACTs* belong to Clade III, which includes mainly members which accept a diverse range of hydroxylated substrates and use acetyl-CoA as the main acyl donor (D'Auria 2006). Interestingly, the ACTs known to be involved in Taxol biosynthesis belong to Clade V.

1101

1102 **Data source figure legends**

1103

1104 **Figure 1-source data 1.**

1105 cDNAs identified in the *C. forskohlii* root cork transcriptome and cloned during this work, with the
1106 GeneBank accession numbers

1107

1108 **Figure 1-source data 2.**

1109 Table of FPKM (Fragments Per Kilobase of transcript per Million mapped reads) values of the first
1110 20 most abundant cDNAs identified in the root cork transcriptome library. cDNAs involved in
1111 terpenoid metabolism are marked in bold.

1112

1113 **Figure 1-source data 3.**

1114 Table of primers used in this study. Construction of plasmids for expression of CfTPS2, CfTPS3,
1115 CfTPS1 is described in (**Andersen-Ranberg et al., 2016**). U (uracil, marked in bold), represents the
1116 cleavage site, used in the USER cloning (**Nour-Eldin et al., 2006**)

1117

1118 **Figure 4-source data 1.**

1119 NMR spectra's of selected ¹³R-manoyl oxide derived molecules

1120

1121

Table 1.

¹H-NMR and ¹³C-NMR chemical shifts (**Figure 4-source data 1**) of novel oxygenated 13*R*-(+)-manoyl oxide-derived diterpenoids formed following transient expression of CYP encoding genes from *C. forskohlii*.

Pos.	19-hydroxy- 13 <i>R</i> -manoyl oxide (3c) ^a		2-hydroxy- 13 <i>R</i> -manoyl oxide (3b) ^a		1,11-dihydroxy- 13 <i>R</i> -manoyl oxide (5d) ^a	
	¹ H (nH; m; J(Hz))	¹³ C	¹ H (nH; m; J(Hz))	¹³ C	¹ H (nH; m; J(Hz))	¹³ C
1	0.89 (1H; m) 1.63 (1H; m)	39.1	1.10 (1H; t(br); 11.9, 11.9) 1.77 (1H; m)	51.3	3.49 (1H; dd; 11.1, 4.5)	79.0
2	1.44 (1H; m) 1.56 (1H; m)	18.1	3.92 (1H; m)	65.3	1.75 (1H; td; 13.5, 11.1, 3.9) 1.60 (1H; m)	29.0
3	0.95 (1H; m) 1.78 (1H; m)	35.8	0.76 (1H; t(br); 11.9, 11.9) 1.99 (1H; d(br); 11.9)	48.2	1.47 (1H; dd; 13.6, 3.9) 1.39 (1H; td; 13.5, 3.6)	39.6
4		38.5		34.9		33.4
5	1.10 (1H; dd; 2.3, 12.6)	56.9	0.95 (1H; dd; 2.2, 12.4)	55.9	0.84 (1H; dd; 11.3, 2.0)	55.6
6	1.36 (1H; dd; 3.6, 12.6) 1.75 (1H; m)	20.1	1.68 (1H; m) 1.27 (1H; m) 1.45 (1H; dd(br); 3.6, 12.5)	19.7	1.47 (1H; m) 1.64 (1H; m)	20.2
7	1.42 (1H; m) 1.83 (1H; dt; 3.3, 12.2)	43.6	1.85 (1H; dt(br); 2.9, 12.5)	43.2	1.48 (1H; m) 1.85 (1H; m)	44.0
8		75.1		75.1		75.3
9	1.35 (1H; dd; 4.3, 12.0)	55.7	1.40 (1H; dd; 4.2, 11.9)	55.4	1.54 (1H; d; 5.8)	55.8
10		37.3		38.7		43.8
11	1.48 (1H; m) 1.58 (1H; m)	15.4	1.53 (1H; m) 1.61 (1H; m)	15.6	4.38 (1H; br q; ≈8.6)	65.6
12	1.78 (1H; m) 1.64 (1H; m)	35.7	1.78 (1H; m) 1.66 (1H; m)	35.5	2.02 (1H; dd; 14.3, 8.7) 2.27 (1H; dd; 14.3, 8.7)	35.8
13		73.4		73.4		72.8
14	5.87 (1H; dd; 10.8, 17.4)	147.7	5.87 (1H; dd; 10.8, 17.4)	147.7	5.90 (1H; dd; 17.4, 10.8)	147.1
15	4.92 (1H; dd; 1.5, 10.8) 5.14 (1H; dd; 1.5, 17.4)	110.2	4.92 (1H; d; 10.8) 5.14 (1H; d; 17.4)	110.3	4.94 (1H; dd; 10.7, 1.5) 5.17 (1H; dd; 17.4, 1.5)	111.2
16	1.27 (3H; s)	28.5	1.27 (3H; s)	28.7	1.27 (3H; s)	32.1
17	1.28 (3H; s)	25.3	1.29 (3H; s)	25.7	1.49 (3H; s)	27.8
18	0.97 (3H; s)	26.8	0.93 (3H; s)	33.5	0.78 (3H; s)	13.5
19	3.70 (1H; d; 10.9) 3.46 (1H; d; 10.9)	65.4	0.85 (3H; s)	22.2	0.85 (3H; s)	32.8
20	0.78 (3H; s)	15.7	0.84 (3H; s)	16.5	0.79 (3H; s)	21.1

^a¹H and ¹³C NMR data acquired at 600 and 150 MHz, respectively, in methanol-*d*₄, at 300 K. s = singlet, d = doublet, t = triplet, m = multiplet, br = broad

1130

1131 **Table 2.**

1132 Structural identification of four oxygenated 13*R*-manoyl oxide-derived diterpenoids formed
 1133 following transient expression of CYP encoding genes from *C. forskohlii* based on comparison of
 1134 their ¹H-NMR and ¹³C-NMR (**Figure 4-source data 1**) chemical shifts to literature data. Chemical
 1135 shifts for reference compounds marked with * have not been assigned to a specific carbon. The ¹³C
 1136 chemical shifts of 9-deoxyforskolin (*Gabetta et al., 1989*) were used as reference for 6,7-
 1137 dihydroxy-11-oxo-13*R*-manoyl oxide (**7h**).

Pos.	9-deoxydeacetylforskolin (10b) ^a			1,9-dideoxydeacetylforskolin (7h) ^a			11-oxo-13 <i>R</i> - manoyl oxide (2) ^a		Coleorol (3a) ^a	
	¹ H (nH; m; J(Hz))	¹³ C	(<i>Gabetta et al., 1989</i>)	¹ H (nH; m; J(Hz))	¹³ C	(<i>Gabetta et al., 1989</i>)	¹³ C	(<i>Gabetta et al., 1989</i>)	¹³ C	(<i>Asada et al., 2012</i>)
1	4.38 (1H; t; 2.8)	71.6	71.2	2.45 (1H, d(br); 13.1)	41.5	43.1	42.1	41.9	31.7	31.6
2	1.47 (1H; m) 2.14 (1H; m) 1.12 (1H; dt; 3.4, 13.2)	25.8	25.6	0.78 (H; m) 1.78 (H; m) 1.40 (H; m)	18.7	18.4	18.5	18.4	18.6	18.4
3	1.62 (1H; dt; 3.5, 13.5)	36.4	36.3	1.36 (H; m) 1.15 (H; m)	43.8	43.7	43.4	43.3	41.9	41.8
4		34.2	34.1		34.4	34.1	33.4	33.2	33.3	33.2
5	1.34 (1H; d; 2.1)	47.5	47.4	n.d.	55.7	55.2	56.0	55.8	45.7	45.5
6	4.44 (1H; t; 2.6)	70.8	70.2	4.39 (1H; m)	70.4	70.2	19.8	19.7	19.5	19.4
7	3.68 (1H; d; 3.6)	80.7	81.1	3.71 (1H; d; 3.8)	81.0	80.7	39.6	39.4	36.6	36.4
8		80.0	78.5		80.1	79.9	77.5	77.2	78.0	77.8
9	3.32 (1H; s)	58.0	58.2	2.59 (1H; s)	65.5	65.4	66.9	66.7	75.3	75.2
10		42.2	41.7		38.0	37.8	37.3	37.1	41.1	40.9
11		207.7	207.6		206.3	205.7	207.7	207.1	21.1	21.0
12	2.63 (1H; d; 18.0) 2.69 (1H; d; 18.0)	49.8	49.9	2.60 (1H; d; 18.1) 2.66 (1H; d; 18.1)	50.0	49.8	50.4	50.2	31.6	31.5
13		75.1	74.8		75.1	75.1	75.1	74.4	72.9	72.8
14	5.94 (1H; dd; 10.8, 17.4)	146.2	145.8	5.95 (1H; dd; 10.7, 17.4)	146.9	146.4	146.9	146.0	147.4	147.3
15	5.04 (1H; d; 10.8) 5.14 (1H; d; 17.4)	112.4	112.7	5.04 (1H; d; 10.7) 5.17 (1H; d; 17.4)	112.3	112.1	112.3	111.9	110.1	110.0
16	1.30 (3H; s)	31.5	31.5*	1.28 (3H; s)	31.6	33.2*	31.4	31.2*	28.9	28.8
17	1.54 (3H; s)	24.1	24.5*	1.50 (3H; s)	23.5	31.4*	28.1	27.9*	27.0	29.9
18	1.38 (3H; s)	33.1	18.2*	0.97 (3H; s)	33.4	23.9*	15.6	15.5*	33.7	33.6
19	1.21 (3H; s)	23.7	23.6*	1.21 (3H; s)	24.0	23.7*	21.8	21.6*	21.5	21.4
20	1.01 (3H; s)	18.5	32.8*	1.30 (3H; s)	17.2	16.7*	33.6	33.5*	17.0	16.8

1138 ^a¹H and ¹³C NMR data acquired at 600 and 150 MHz, respectively, in methanol-*d*₄, at 300 K. s = singlet, d = doublet, t
 1139 = triplet, m = multiplet, br = broad

1140

1141 **Table 3.**
 1142 Overview of 13*R*-manoyl oxide-derived diterpenoids identified in *N. benthamiana*, expressing
 1143 combinations of *C. forskohlii* genes encoding CYPs and acetyltransferases together with genes
 1144 encoding the required enzymes for biosynthesis of 13*R*-manoyl oxide (*Cf*DXS, *Cf*GGPPs, *Cf*TP2 and
 1145 *Cf*TPS3). GC-MS and LC-qTOF-MS chromatograms of the identified diterpenoids are shown in
 1146 previous figures.
 1147

		Single CYPs		Two CYPs		Three CYPs		ACTs		Standards	
		CYP71D781 CYP76AH16 CYP76AH11 CYP76AH17 CYP76AH8 CYP76AH15		CYP76AH15+CYP76AH16 CYP76AH8+CYP76AH16 CYP76AH15+CYP76AH16 CYP76AH17+CYP76AH16 CYP76AH17+CYP76AH11 CYP76AH8+CYP76AH11 CYP76AH15+CYP76AH11		CYP76AH17+CYP76AH16 CYP76AH8+CYP76AH16 CYP76AH15+CYP76AH11+CYP76AH16 CYP76AH15+CYP76AH11+CYP76AH16		CYP76AH15+CYP76AH11+CYP76AH16+ACT1-8 CYP76AH15+CYP76AH11+CYP76AH16+ACT1-6		Forskolin STD (16c) Deacetylforforskolin STD (13b) 9-deoxydeacetylforforskolin STD (10b) 1,11-dihydroxy-13 <i>R</i> -manoyl oxide(5d) 1,9'-dideoxydeacetylforforskolin (7n) STD mix 9-hydroxy-13 <i>R</i> -manoyl oxide STD (3a) 11-oxo-13 <i>R</i> -manoyl oxide STD (2)	
		(-)									
GC-MS	#										
	1	13 <i>R</i> -(-)-manoyl oxide	x								
	2	11-oxo-13 <i>R</i> -manoyl oxide		x	x	x				x	
	3	9-hydroxy-13 <i>R</i> -manoyl oxide								x	
	3	2-hydroxy-13 <i>R</i> -manoyl oxide									
	3	19-hydroxy-13 <i>R</i> -manoyl oxide									
		MO deriv.	MF	RT [min]	Mw [Da]	m/z[M+N]	ΔM (amu.)				
LC-qTOF-MS	4	MO(O)	C ₂₀ H ₃₂ O ₃	19. 66	### ###	### ###	#				
	a	(OH)									
	4	MO(O)	C ₂₀ H ₃₂ O ₃	22. 50	### ###	### ###	#				
	b	(OH)									
	4	MO(O)	C ₂₀ H ₃₂ O ₃	24. 90	### ###	### ###	t r	3 . 5	1 . 5	1 . 5	#
	c	(OH)					#	#			
	4	MO(O)	C ₂₀ H ₃₂ O ₃	26. 63	### ###	### ###	1 . 5				
	d	(OH)									
	5	MO(O	C ₂₀ H ₃₄ O ₃	16. 46	### ###	### ###	#				
	a	H) ₂									
LC-qTOF-MS	5	MO(O	C ₂₀ H ₃₄ O ₃	18. 90	### ###	### ###	#				
	b	H) ₂									
	5	MO(O	C ₂₀ H ₃₄ O ₃	21. 20	### ###	### ###	3 . 1				
	c	H) ₂									
	5	MO(O	C ₂₀ H ₃₄ O ₃	22. 28	### ###	### ###	t r	# #	# #	# #	1. 2
	d	H) ₂									
	5	MO(O	C ₂₀ H ₃₄ O ₃	27. 50	### ###	### ###	3 . 7				
	e	H) ₂					# # #				

